Document:

exv10w69

Exhibit 10.69

FORM OF OEM SUPPLY AND PURCHASE AGREEMENT

          This OEM Supply and Purchase Agreement (“Agreement”) is made as of January 1, 2008 (the
“Effective Date”) by and between Nihon Kohden Corporation with offices at 31-4 Nishiochiai 1-chome,
Shinjuku-ku, Tokyo 161-8560 Japan (hereinafter referred to as “NK”), and Cardiac Science
Corporation, formerly known as Cardiac Science Inc., with offices at 3303 Monte Villa Parkway,
Bothell, Washington, USA 98021 (hereinafter referred to as “CSC”) (NK and CSC each being a “Party”,
and collectively the “Parties”).

RECITALS

          CSC is a manufacturer of various medical devices including, without limitation, an automated
external defibrillator known as the AED 9231 (the “AED 9231”) and Replacement Electrodes referred
to collectively as “Products” as defined in Appendix 1 below which, among other things, externally
defibrillate a human heart.

          NK develops, manufactures, distributes and sells various medical devices and systems including
patient monitoring systems and defibrillators.

          NK and CSC previously entered into an OEM Supply and Purchase Agreement, dated March 1, 2002,
as amended by Amendment No. 1 dated March 16, 2005 (the “Prior Agreement”) for the purchase and
sale of Products. The term of the Prior Agreement expires on December 31, 2007. NK desires to
continue to purchase from CSC, and CSC desires to continue to sell to NK AED 9231s and Replacement
Electrodes made by CSC for resale under one or more of NK’s trademarks or brand names. CSC
Products sold under the NK trademark or brand name will be sold exclusively by NK.

          NOW THEREFORE, in consideration of the mutual promises and covenants hereinafter contained,
and other consideration the receipt and sufficiency of which is hereby acknowledged, it is hereby
agreed between the parties as follows:

TERMS AND CONDITIONS

1. GRANT OF RIGHTS

          1.1 License. Subject to the terms of this Agreement, CSC grants to NK the
non-assignable and non-transferable right and license to:

               (a) Resell and sub-license the NK-branded AED 9231s to end-users or to other third parties
for sale;

               (b) Resell and sub-license the Replacement Electrodes to end-users or to other third parties
for sale and sub-license to end-users for use only with AED 9231s;

 

[*]  Designates portions of this document that have been omitted pursuant to a request for
confidential treatment filed separately with the Commission.

 

 

          (c) Use CSC Marks in connection with the marketing, resale and sublicensing of Products,
pursuant to CSC’s prior written approval, such approval not to be unreasonably withheld; and

          (d) Resell and sub-license the Products as provided herein under NK’s own Marks and using
NK’s own labeling and packaging; provided, however, that NK maintains all CSC Marks and other
proprietary notices contained on the Products.

     1.2 Exclusive Appointment. CSC appoints NK as it exclusive distributor to market,
sell and distribute the AED 9231 to end user customers in Japan during the Term. Throughout the
Term, NK shall use its best efforts to market, sell and distribute AED 9231 in Japan. NK may
supplement, but not replace, its marketing, sales and distribution of AED 9231s in Japan with the
marketing, sales and distribution of AED 1200s that contain circuit boards purchased from CSC under
the OEM Supply and Purchase Agreement dated March 31, 2005 or any successor agreement (the “Parts
Agreement”). For the avoidance of doubt, the AED 1200 is referred to in the Parts Agreement as the
AED 1x.

     1.3 Enforcement. NK shall enforce its obligations under this Agreement with respect
to sublicenses granted by NK pursuant to this Agreement and, upon the request of CSC, shall
enforce, at NK’s cost, the rights of CSC with respect to any such sublicense and shall cooperate
with CSC, at NK’s cost, in any action by CSC to enforce its rights with respect to any such
sublicense, including by providing to CSC all information and assistance that CSC considers
reasonably useful to pursue such action. NK’s sale, distribution or other transfer of Products to
a distributor or a third party for resale to an End-User shall not prevent CSC from enforcing its
rights pursuant to this section.

     1.4 Reservation of Rights. Except as expressly provided herein, CSC does not grant
to NK any license or Intellectual Property Rights, whether by implication, estoppel or otherwise in
and to the Products, CSC Marks and CSC Confidential Information. NK shall not: (a) reverse
engineer, decompile, or otherwise tamper with the Products; (b) permit any third party including
distributors or end user customers to do any of the foregoing.

2. SCOPE OF THE OEM SUPPLY AND PURCHASE AGREEMENT

     2.1 For the term of this Agreement, on the terms and conditions provided herein, CSC agrees
to sell and NK agrees to purchase the Products more closely specified in Appendix 1 hereto in such
quantities as NK orders from time to time pursuant to Section 3.

     2.2 CSC shall supply to NK Products that conform to the technical specifications defined in
Appendix 3 hereto and in accordance with the warranty in Section 9.1.

     2.3 Parties shall cooperate and provide to each other in a timely fashion all information
necessary to facilitate the OEM version of the AED 9231s.

 

[*]  Designates portions of this document that have been omitted pursuant to a request for
confidential treatment filed separately with the Commission.

- 2 -

 

     2.4 NK agrees to pay CSC for any and all non-recurring engineering (“NRE”) costs and other
expenses associated with any modifications to the Products requested by NK including the NK color
and labeling under one or more of NK’s trademarks or brand names and any modifications to the
casing, internal electronics, software or interfaces of the AED 9231. The Parties will agree in
advance as to the nature and the amount of the NRE costs and expenses associated with the
aforementioned modifications.

     2.5 All artwork, packages and labels (if any) prepared by CSC in connection with the NK name
shall be sent to NK for approval.

     2.6 For convenient reference, certain of the capitalized terms used in this Agreement is
defined in Appendix 4.

     2.7 During the Term, NK shall not, directly or indirectly (e.g., through any Affiliate or
distributor), promote, market, sell or distribute any product that directly competes with the AED
9231. However, for purposes of this Section 2.7 any automated external defibrillator with a lower
specification than AED 9231, including but not limited to an AED 1200 that contains circuit boards
purchased from CSC under the Parts Agreement and any automated external defibrillator equivalent or
similar to the AED 1200, shall not be considered to be a product that competes with the AED 9231.

     2.8 NK shall not, directly or indirectly (e.g., through any Affiliate or distributor),
promote, market, sell or distribute any AED 9231 or AED 1200 in North America.

3. TERM AND TERMINATION

     3.1 Duration. This Agreement becomes effective as of the Effective Date and
continues in full force and effect, unless sooner terminated as set forth below, until [*] (the
“Term”).

     3.2 Termination. Either Party may terminate this Agreement by giving the other Party
written notice of termination at least one (1) year prior to the effective date of such
termination. Either party (the “terminating party”) may immediately terminate this Agreement upon
notice to the other in the event that the other party: (a) breaches any material term of this
Agreement, including the obligation to pay amounts due under this Agreement and such breach is not
cured within thirty (30) days after notice from the terminating party; or (b) immediately upon
written notice to the other party in the event that proceedings in bankruptcy or insolvency are
instituted by or against the other party, or a receiver is appointed, or if any substantial part of
the assets of the other party is the object of attachment, sequestration or other type of
comparable proceeding, and such proceeding is not vacated or terminated within thirty (30) days
after its commencement or institution

     3.3 Effect of Expiration or Termination. Upon any expiration or termination of this
Agreement, the following provisions apply:

 

[*]  Designates portions of this document that have been omitted pursuant to a request for
confidential treatment filed separately with the Commission.

- 3 -

 

          (a) NK will promptly remit to CSC all money due as of the date of expiration or termination;
and if CSC terminates this Agreement pursuant to Section 3.2(a), then NK shall reimburse CSC for
its actual costs of raw materials and components used to manufacture the Products which CSC has
procured in order to supply the Products anticipated by this Agreement, and all work-in-process
related to such Products; provided, however, that (i)NK shall only be required to reimburse CSC for
such volume of raw materials, components and work-in-process that CSC reasonably determines is
unable to utilize for any reasonable period in products other than the Products; and (ii) the
amount of any such reimbursement shall be reduced by any refunds that CSC is able to obtain upon
making reasonable efforts to return such raw materials and components to the vendors thereof. In
the event of termination of this Agreement NK may sell and sublicense the Products existing in its
inventory at expiration or termination.

          (b) For a period of up to nine (9) months after the expiration or termination of this
Agreement, NK may continue to sell Products existing in its inventory at expiration or termination.

          (c) Except in connection with sales under (b) above, NK shall have no further right to use
CSC’s Marks and shall return all promotional materials that contain CSC Marks to CSC.

          (d) NK promptly shall return to CSC all CSC Confidential Information in NK’s possession. NK
shall be entitled to retain, however, copies any data and information that NK may be obligated to
retain for Quality Control and warranty purposes and/or the requirements of any government agency
or applicable law.

          (e) NK shall have a right to keep providing support for the Product to end user customers
after expiration or termination of this Agreement. For that purpose, CSC shall continue to supply
Replacement Electrodes and all other necessary parts and accessories to NK at its standard
published dealer prices under such terms that are mutually agreeable to the parties, and NK may
sell such Replacement Electrodes, parts and accessories to such customers.

          (f) In the event of any termination of this Agreement by NK pursuant to the first sentence of
Section 3.2, then, upon CSC’s request, NK shall cooperate and assist CSC to obtain JMHW and any
other regulatory approval required for CSC to directly or indirectly (e.g., through another
distributor) promote, market, sell and distribute Products in the Territory after the end of the
Term. Such cooperation and assistance may include, without limitation, the transfer of any such
approvals held by NK to CSC or its designee.

          (g) Neither party shall by reason of the termination or expiration of this Agreement in
accordance with its terms be liable to the other for compensation, reimbursement or damages on
account of lost prospective profits or anticipated sales, or on account of expenditures,
investments, leaves or commitments by the other or on any other account.

 

[*]  Designates portions of this document that have been omitted pursuant to a request for
confidential treatment filed separately with the Commission.

- 4 -

 

4. NK OBLIGATIONS

     4.1 Applicable Laws.

          (a) NK shall comply with all applicable laws, rules and regulations in all of its activities
relating to this Agreement including the U.S. export laws, and to the marketing, sale, lease,
license, promotion, distribution, export, import and transfer of the Products, including without
limitation, obtaining any and all registrations and licenses required for the operation of NK’s
business and the marketing, sale, lease, license, promotion, distribution, export, import and
transfer the Products.

          (b) NK shall be solely responsible for and agrees to provide, in connection with the sale,
offer to sell, license, lease, import, export, transfer or distribution of Products, such labeling,
manuals, or other information as may be required by applicable laws, including but not limited to
instructions, warning and preventions.

          (c) NK shall maintain in effect, pursuant to applicable laws including but not limited to
21CFR 821 of the U.S. Code of Federal Regulations, a system of tracking each of the Products, and
shall provide such information to CSC. Such a system shall, at a minimum enable CSC to promptly:

     (i) identify each Product to its final and/or current location.

     (ii) if appropriate to recall, remedy, repair or modify any or all of the Products,
and/or notify the owners or possessors thereof, in the event of a recall affecting the
Products;

     4.2 Documentation and Models. NK shall provide CSC with one copy of the operations
manuals for each AED 9231 model sold under NK’s trade name. When a manual is revised, a copy of
the revised manual will be provided within 30 days after the revised manual is first issued.

     4.3 Responsibility. NK shall be jointly and severally liable to CSC for the actions
and omissions of its officers, employees, agents, directors, representatives, distributors,
sub-dealers, End-Users and other sublicenses with respect to performance under any license or
sub-license granted or authorized hereunder or related to the subject matter thereof.

5. CSC OBLIGATIONS

     5.1 Supply. CSC shall provide Products to NK pursuant to the terms and conditions
specified herein. Notwithstanding the foregoing, CSC shall be relieved of the obligation to supply
such Products in the event that any of the following circumstances occurs: (i) a third party
claims that any of the Products infringes or misappropriates its intellectual property; and

 

[*]  Designates portions of this document that have been omitted pursuant to a request for
confidential treatment filed separately with the Commission.

- 5 -

 

(ii) any product recall involving any of the Products. CSC shall not be required to provide
any direct support to End-users unless mutually agreed upon by CSC and NK in writing.

     5.2 Modifications. NK may request modifications to the Products, which would result
in a deviation from the description of the Products in the Technical Specifications which is
specified in Appendix 3; provided such a request is made at least ninety (90) days prior to the
desired effective date of such modification. The parties shall negotiate in good faith any such
requested modification, including any related amendments to this Agreement to provide for
reimbursement for any non-recurring costs that CSC will incur to effect such modifications and any
adjustments to the prices hereunder to reflect any increased costs of manufacturing the Products as
a result of such modification. If the parties are unable to agree upon such requested modification
and related amendments to this Agreement within such ninety (90) day period, this Agreement and the
Document shall continue in effect without change;

     5.3 Training. CSC shall provide training on the Products for certain NK’s sales
personnel, engineers or its clinical specialists. CSC’s training on the Products will be provided
as reasonably agreed upon by the parties.

     5.4 CSC Product Changes. CSC shall inform NK about any material changes of
specification or any other material changes to the Products at least 180 days prior to their
implementation. If the proposed modification might affect the performance, quality or functioning
of the Products or the approvals, permissions, consents or licenses applicable to them, CSC shall
not modify the Products unless NK has given its consent to the modification in writing. If NK
gives its consent to the proposed modification, the modified Products shall replace the prior
version of the Products and the terms and conditions of this Agreement shall continue to apply. If
the modified Products are not acceptable to NK, CSC shall, if feasible, continue to deliver to NK
unmodified Products. Concerning the Replacement Electrodes, if the modification relates to a
change in the gel material, CSC shall provide NK with the modification notice and biocompatibility
data at least 180 days prior to the proposed date of shipment of the modified Replacement
Electrodes.

     5.5 Out of warranty service. With respect to out-of-warranty product returns, CSC
shall agree to repair the out of warranty Product for a period of at least seven (7) years from the
date of delivery by CSC of the Product. NK shall contact CSC and inform CSC of the relevant
information and request a returned goods authorization and upon approval by CSC, CSC shall give a
return authorization number within two (2) days from receiving the request from NK. As promptly as
possible, but not later than ten (10) working days after CSC’s receipt of the out of warranty
Products, CSC shall to the extent possible repair the out of warranty Product. CSC shall provide a
report together with any product being returned. Each Party shall bear its own shipping costs.
The risk of loss or damage to the product shall pass to the other party upon delivery to the other
party’s carrier. CSC shall apply its standard service rate to such out of warranty repairs, unless
cost of repair is estimated to exceed $200. In such cases, NK shall have

 

[*]  Designates portions of this document that have been omitted pursuant to a request for
confidential treatment filed separately with the Commission.

- 6 -

 

the right to approve in advance the nature and the amount of the repair costs and expenses
associated with the out of warranty Product requiring repairs.

     5.6 Product Discontinuation. If CSC plans to discontinue manufacturing of any of the
Product from its product line, it shall notify NK about the intended removal in writing at least
240 days in advance. CSC will make its best commercial effort to provide substitute product if
Product, as defined in Appendix 1, is discontinued.

     5.7 Spare Parts. CSC will make best effort to make compatible spare parts available
on reasonable commercial terms for a period of at least [*] from the delivery by CSC of the Product
in question. NK understands that there may be no spare parts for the Products other than the
Products themselves or their replacements. Accordingly, in such cases where spare parts are
reasonably required for necessary repair of such Products, CSC shall replace the Product in
question with replacements that are reasonably acceptable to NK and on reasonable commercial terms.

     5.8 Applicable Laws and Regulations.

          (a) CSC shall manufacture the Products in compliance with FDA, ISO 9001, the MDD (the Counsel
Directive 93/42/EEC concerning medical devices promulgated by the Counsel of the European
Communities as amended) and all other applicable laws and regulations.

          (b) CSC shall assist and cooperate with NK’s efforts, to the extent reasonably necessary, in
obtaining any regulatory approvals necessary for the use of the Products. In this case of JMHW,
the parties shall cooperate with each other to attain necessary approvals.

     5.9 CSC Notification. Notification of quality control and assurance from CSC to NK
shall be as set forth in Appendix 5. CSC will indemnify and hold NK harmless from and against any
and all direct damages sustained as the result of CSC’s failure to provide timely notice of Product
failure or defect as detailed in the Appendix 5.

6. ORDERS

     Unless expressly otherwise agreed, all sales under this Agreement shall be between CSC as
seller and NK as purchaser.

     6.1 NK shall submit to CSC periodic forecasts every month of its anticipated requirement of
the Products for the subsequent five (5) month period. The purchase forecasts are not binding on
NK. The forecasts shall be provided in good faith. CSC shall notify NK of any inability as a
result of causes beyond CSC’s control (i.e. Force Majeure) to supply according to NK’s forecasts no
later than four (4) weeks prior to the forecast date of shipment and in such case shall inform NK
of the maximum amount it is able to supply and its shipment schedule.

 

[*]  Designates portions of this document that have been omitted pursuant to a request for
confidential treatment filed separately with the Commission.

- 7 -

 

     6.2 NK shall order Products from CSC by issuing written purchase orders. Purchase orders for
AED 9231s shall be issued at least sixty (60) days in advance of the requested shipment date.
Purchase orders for Electrodes shall be issued at least thirty (30) days in advance of the
requested shipment date.

     6.3 Unless otherwise agreed between the Parties, NK may reschedule in writing, delivery of
any Product on purchase orders with CSC within the following guidelines:

	 	 	 
	Days from Scheduled Shipment Date:	 	Allowed Changes
	AED 9231s [*] days

	 	No changes
	 
	 	 
	AED 9231s –[*] days

	 	[*] percent (plus or minus)
	 
	 	 
	AED 9231s –[*] days

	 	[*] percent (plus or minus)

	 	 	 
	Days from Scheduled Shipment Date	 	Allowed Changes
	Electrodes [*] days

	 	No changes
	 
	 	 
	Electrodes [*] days

	 	[*] percent (plus or minus)
	 
	 	 
	Electrodes [*] days

	 	[*] percent (plus or minus)

     6.4 Every purchase order given by NK will be deemed to be a separate purchase contract under
the terms of this Agreement. Cardiac Science may at its sole discretion refuse to accept or may
cancel any outstanding purchase order in the event that any of the following circumstances occurs:
(i) CSC determines or a third party claims that any of the Products infringes or misappropriates
its intellectual property; and (ii) any product recall or similar corrective action involving any
of the Products which is required to be reported under the FDA’s Medical Device Reporting
requirements such as 21 CFF Part 803.

7. DELIVERIES

     7.1 Delivery and Shipping. Unless expressly otherwise agreed in writing, all orders
shall be delivered by CSC EXW CSC’s manufacturing plant in Deerfield, WI or another location of
CSC’s choosing, interpreted in accordance with INCOTERMS (2000 Edition). CSC shall use its
commercially reasonable efforts to ship the Products with test reports in time for them to arrive
by delivery dates agreed upon in compliance with the ordering procedure described herein. CSC
shall notify NK of any anticipated delivery problems in advance, but CSC shall not be responsible
for any loss or liability suffered by NK as a result of delay in delivery or replacement of any
order. NK agrees, however, that for shipments destined to locations outside the U.S.,

 

[*]  Designates portions of this document that have been omitted pursuant to a request for
confidential treatment filed separately with the Commission.

- 8 -

 

where transit time is expected to take more than one week, the minimum lead time for orders
may be appropriately increased by CSC to reasonably account for such additional transit time.
Title and risk of loss to Products purchased under this Agreement shall pass to NK upon delivery
thereof to the carrier.

     7.2 Packaging. Unless NK specifies otherwise, deliveries of the Products shall be
made in CSC’s standard delivery containers, which are reasonably designed to avoid damage during
delivery and inventory phases. Delivery shall be made to such address as NK specifies in a
purchase order. NK shall pay reasonable costs of any special packaging that it requires.

     7.3 Taxes. Except as expressly stated otherwise, prices set forth herein do not
include any existing or future taxes, tariffs, fees, duties, assessments or other charges (other
than income taxes assessed on CSC) that may be applicable to the Products supplied to NK pursuant
to this Agreement. If such additional sums are required to be withheld, collected, or paid, then
CSC shall add them to the price payable by NK.

     7.4 Acceptance and Non-Conforming Products. All sales of Products to NK shall be
deemed accepted upon shipment by CSC and title to the Products shall pass to NK upon delivery to
NK’s carrier. NK shall inspect Products promptly upon receipt at the shipping destination in
accordance with incoming inspection criteria mutually agreed upon by the Parties to determine if
any Products are non-conforming. Upon reasonable request, CSC shall provide reasonable assistance
to NK in order to determine whether any of the Products are non-conforming. Non-conforming
Products may be returned freight prepaid to CSC after receipt of a return authorization number from
CSC. CSC shall issue a return authorization number within two (2) days from receiving information
from NK. No returns will be accepted without a return authorization number. As promptly as
possible, but not later than ten (10) working days after CSC’s receipt of properly rejected goods,
CSC shall, at its option and expense, either repair or replace non-conforming Products. CSC shall
provide a repair/replacement report together with any product being returned. Title and risk of
loss or damage to the products shall pass to the other party upon delivery to the other party’s
carrier. CSC will prepay transportation charges back to NK and shall reimburse NK for any costs of
transportation incurred by NK in connection with the return to CSC of properly rejected goods.
Other than as permitted in this Section or under the terms of the warranty stated herein, goods may
not be returned to CSC.

     7.5 Failure to Pay Duties. NK shall bear all applicable taxes (such as sales, use or
similar taxes); all customs, duties, and similar charges; and all personal property taxes
assessable on Products after delivery to the carrier at CSC’s plant. In the event of NK’s failure
to pay any amounts due CSC within the time herein provided, CSC may, in addition to other remedies
available to it, cease acceptance and /or delivery of orders for Products from NK until such time
as NK’s payments are current and may thereafter condition acceptance and delivery of future orders
on such other or additional payment terms as it shall, in its discretion, determine.

 

[*]  Designates portions of this document that have been omitted pursuant to a request for
confidential treatment filed separately with the Commission.

- 9 -

 

     7.6 Inspection. NK may, by itself or through its appointed representative, during
regular business hours and following reasonable notice to CSC, inspect CSC’s physical facilities
and CSC’s quality control procedures in order to assure compliance with the specifications, quality
requirements and other applicable standards. In the event that NK determines that the quality
procedures applied by CSC are insufficient as to ensure consistent acceptable quality, NK shall
specifically inform CSC thereof and of its recommended corrective measures to be undertaken by CSC.
CSC agrees to evaluate such recommendation in good faith. CSC agrees to take all appropriate
measures in order to ensure compliance of its sub-suppliers with the foregoing. Any circumstance
which might lead to modification or cancellation of CSC’s ISO quality system certificate(s) or
status as an FDA registered manufacturer in good standing, shall be immediately informed to NK in
writing.

8. PRICES AND TERMS OF PAYMENT

     8.1 Prices. The prices for the Products shall be as set forth in Appendix 2 and,
unless expressly otherwise agreed by the Parties, CSC shall sell and NK shall purchase the Products
during the Term from the Effective Date to [*] at those prices. Prices after [*] shall be based
upon mutual agreement of the parties and minimum quantity targets by NK. The Parties shall consult
and cooperate to agree upon the prices and minimum quantity targets for each Product to be
purchased by NK under this Agreement during any NK fiscal year (i.e. April 1 to the following
March 31) commencing after [*] no later than [*] of the prior year.

     8.2 Credit. Any credit terms set forth for NK hereunder shall be subject to the
condition that open account credit is established and maintained to CSC’s satisfaction and that
shipment of any delivery will not cause NK to exceed such credit limit as CSC may from time to time
establish. Unless expressly otherwise agreed in writing, payment for all Products shall be made by
NK in US dollars by wire transfer within thirty (30) days from the date of arrival of the Products
at NK’s premises or such other destination as may have been specified in the purchase order. In
addition to all of the other rights and remedies to which CSC shall be entitled, CSC shall be
entitled to interest on overdue payments at the rate of twelve (12) per cent per annum or highest
rate permitted by the applicable law, whichever is lower. In the event of NK’s failure to pay any
amounts due CSC within the time herein provided, CSC may, in addition to other remedies available
to it, cease acceptance and/or delivery of orders for Products from NK until such time as NK’s
payments are current.

9. CSC REPRESENTATIONS AND WARRANTIES

     9.1 General. CSC’s warranty obligations for the Products supplied by CSC shall be
set forth in subsection (a) — (e) below:

          (a) CSC represents and warrants that the Products supplied by CSC shall be in accordance with
the specifications and quality requirements specified in this Agreement and free from defects or
faults in design workmanship and materials for a period of five (5) years after

 
 

[*]  Designates portions of this document that have been omitted pursuant to a request for confidential treatment filed separately with the Commission.

- 10 -

 

delivery by CSC of each Product to NK. Batteries shall be supplied in accordance with the
specifications and quality requirements specified in this Agreement and shall be warranted for a
period of two (2) years after delivery by CSC to NK;

          (b) Products as provided by CSC, and as of the Effective Date, are in compliance with all
applicable requirements of U.S. and Japanese law or regulation. As stated in Section 13.3 herein,
CSC will make its best effort to be in compliance with applicable regulatory requirements of other
foreign countries in which the Products may be marketed;

          (c) CSC shall maintain quality control procedures in compliance with the requirements of the
following quality systems ISO 13485:2003, US GMP 21 CFR 820 (“the US GMP”) and the Council
Directive 93/42/EEC concerning medical devices promulgated by the Council of the European
Communities as amended (“the MDD”). If requested by NK, CSC shall provide NK with appropriate
documents evidencing that the Products comply with the essential requirements of the MDD and US GMP
product standards. CSC grants NK the right, by itself or through its appointed representative,
during regular business hours and following reasonable notice to CSC, to inspect CSC’s physical
facilities and CSC’s quality control procedures in order to assure compliance with the
specifications, quality requirements and other applicable standards as required by JMHW ordinances.
In the event that NK determines that the quality procedures applied by CSC are insufficient as to
ensure consistent acceptable quality, NK shall specifically inform CSC thereof and of the
reasonable corrective measures recommended to be undertaken by CSC. CSC agrees to consider in good
faith any such recommended corrective measures without delay. CSC agrees to take all appropriate
measures in order to ensure compliance of its sub-suppliers with the foregoing;

          (d) CSC has good and marketable title, and the right to license or sell the Products free and
clear of all liens, security interests and encumbrances;

          (e) CSC has the legal capacity to execute this Agreement and to perform its obligations
hereunder; and execution and delivery of this Agreement by CSC and performance of its obligations
hereunder shall not violate any applicable U.S. laws.

     9.2 Remedies. (a) If CSC breaches any of its warranties described in Section 9.1,
CSC will, in its sole discretion, either: (i) repair or replace the Product under the applicable
warranty, or (ii) refund any fees already paid for the non-conforming goods. If CSC decides to
repair or replace a Product, NK shall contact CSC and inform CSC of the relevant information and
request a returned goods authorization. If CSC gives a returned goods authorization, CSC will bear
shipping costs in transit in both directions; provided, however, CSC will only bear CSC’s shipping
costs to CSC if NK ships via a carrier designated by NK and directs the carrier bill to CSC. Title
and risk of loss or damage to the Product shall pass to the other party upon delivery to the other
party’s carrier. CSC shall ship the repaired or replacement Product to NK with repair/replacement
report as promptly as possible, but not later than ten (10) working days after CSC’s receipt of the
non-confirming Products.

 

[*]  Designates portions of this document that have been omitted pursuant to a request for confidential treatment filed separately with the Commission.

- 11 -

 

     9.3 Limitations.

          (a) THE EXPRESS WARRANTY PROVIDED IN THIS ARTICLE 9 IS THE SOLE AND EXCLUSIVE WARRANTY GIVEN
BY CSC WITH RESPECT TO THE PRODUCTS, AND CSC GIVES AND MAKES NO REPRESENTATIONS OR WARRANTIES OF
ANY KIND, EXPRESS OR IMPLIED, OTHER THAN THE FOREGOING. WITHOUT LIMITING THE GENERALITY OF THE
FOREGOING, NO IMPLIED WARRANTY OF MERCHANTABILITY, NO IMPLIED WARRANTY OF FITNESS FOR A PARTICULAR
PURPOSE, AND NO IMPLIED WARRANTY ARISING BY USAGE OF TRADE, COURSE OF DEALING OR COURSE OF
PERFORMANCE IS GIVEN OR MADE BY CSC OR SHALL ARISE BY OR IN CONNECTION WITH ANY SALE OR PROVISION
OF THE PRODUCTS BY CSC OR NK’S USE OR SALE OF THE PRODUCTS OR NK’s AND CSC’s CONDUCT IN RELATION
THERETO OR TO EACH OTHER. NO REPRESENTATIVE OF CSC IS AUTHORIZED TO GIVE OR MAKE ANY OTHER
REPRESENTATION OR WARRANTY OR TO MODIFY THE FOREGOING WARRANTY IN ANY WAY. THE REMEDIES SET FORTH
IN SUCH EXPRESS WARRANTY ARE THE ONLY REMEDIES AVAILABLE TO ANY PERSON FOR BREACH OF WARRANTY.

          (b) The warranties described in Article 9 do not extend to any Products that have been
subject to misuse, neglect or accident; that have been damaged by causes external to the Products,
including but not limited to failure of or faulty electrical power; that have been used in
violation of CSC’s instructions, inconsistent with the Documentation or outside the scope of the
license granted herein; on which the serial number has been removed or made illegible; or that have
been modified, disassembled, serviced or reassembled by anyone other than CSC or its authorized
agents.

          (c) NK agrees that the warranty, remedies and limitations on liability provided in this
Agreement (subject to the limitations thereon) reflect a bargained-for compromise between CSC and
NK as to the allocation of risk in this Agreement.

10. NK REPRESENTATION AND WARRANTY

     10.1 General. NK represents and warrants:

          (a) As to Products subject to sublicenses granted by NK, NK shall not provide any
representations and warranties to its sublicenses, which exceed in scope the representations and
warranties provided by CSC to NK herein.

          (b) NK has the legal capacity to execute this Agreement and perform its obligations
hereunder;

          (c) Execution and delivery of this Agreement by NK and performance of its obligations
hereunder shall not violate any applicable Japan laws.

 

[*]  Designates portions of this document that have been omitted pursuant to a request for confidential treatment filed separately with the Commission.

- 12 -

 

11. LIMITATION OF LIABILITY EXCEPT PRODUCT LIABILITY

     IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, INCIDENTAL,
CONSEQUENTIAL, SPECIAL OR EXEMPLARY DAMAGES OR LOST PROFITS, EVEN IF ADVISED OF THE POSSIBILITY OF
SUCH DAMAGES. THE LIABILITY OF CSC FOR ANY CLAIM CONCERNING PERFORMANCE OR NONPERFORMANCE BY CSC
PURSUANT TO, OR IN ANY WAY RELATED TO, THE SUBJECT MATTER OF THIS AGREEMENT, REGARDLESS OF THE FORM
OF ACTION, WHETHER IN CONTRACT OR IN TORT, EXCEPT PRODUCT LIABILITY DESCRIBED IN SECTION 12 AND
INFRINGEMENT LIABILITY DESCRIBED IN SECTION 16, SHALL BE LIMITED TO THE AMOUNT PAID TO CSC BY NK
FOR THE LICENSED AED 9231s OR REPLACEMENT ELECTRODES, AS APPLICABLE, IN ACCORDANCE WITH THIS
AGREEMENT AND WITH RESPECT TO WHICH LICENSED AED 9231 OR REPLACEMENT ELECTRODES, AS APPLICABLE,
SUCH CLAIM SPECIFICALLY RELATES. IN NO EVENT SHALL CSC BE LIABLE FOR DAMAGES CAUSED BY NK’s OR ANY
END-USER’S ACT OR OMISSION.

12. PRODUCT LIABILITY

     Notwithstanding anything to the contrary contained herein, CSC agrees to indemnify and hold NK
harmless from and against any and all losses, claims, damages, costs and expenses, including
reasonable attorney’s fees, arising out of or relating to personal injury, illness and/or death if
it is established that such damage and/or personal injury resulted from any i) defect with respect
to design, manufacture, workmanship or materials of the Product; or ii) failure of the Product, at
the time of shipment to NK, to comply with the Technical Specifications which is specified in
Appendix 3; provided that NK shall:

          (a) give CSC prompt written notice of the claim;

          (b) tender defense of the claim to CSC;

          (c) cooperate with CSC in connection with the defense and any settlement of the claim; and

          (d) not settle the claim without the prior written consent of CSC, which consent shall not be
unreasonably withheld.

13. REGULATORY REQUIREMENTS, RECALLS

     13.1 The Parties confirm that in relation to the JMHW regulatory approvals or submission that
CSC shall be regarded as the manufacturer of the Products and NK as the in- country caretaker.

 

[*]  Designates portions of this document that have been omitted pursuant to a request for confidential treatment filed separately with the Commission.

- 13 -

 

     13.2 The Parties agree to cooperate in order to gain JMHW regulatory approval for the
Products including Cardiac Science’s biphasic AED 9231 product. For shipments outside of Japan,
CSC warrants that the Products conform to the requirements established in the MDD for CE marking
and will affix the CE mark to all the Products.

     13.3 Each Party shall make its best efforts to comply with all applicable laws and
regulations of the competent jurisdiction in which NK sells its Products. In particular, each
Party shall ensure that the Products as well as their respective activities in relation thereto
conform to all legislation, rules, regulations and statutory requirements existing from time to
time.

     13.4 If either Party becomes aware of an event where there is reasonable suspicion that the
Product contributed to or caused a death or serious injury or an event where a Product has
malfunctioned and, if that malfunction occurred again, it could cause death or serious injury, then
such Party shall use its best efforts to (a) give the other Party notice thereof orally within 24
hours from the receipt of such complaint or becoming aware of such event and (b) confirm such
notice by email within 24 hours after giving oral notice. As used herein, “Serious injury” means:
Any injury or illness that i) is life threatening, or ii) result in permanent impairment of a body
function or permanent damage to a body structure, or iii) necessities medical or surgical
intervention to preclude permanent impairment of a body function or permanent damage to a body
structure. To be reported a direct link with the Product and its possible short -comings should be
clearly established.

     13.5 The Parties shall be responsible for reporting under United States reporting
requirements such as 21 CFR Part 803, the Japanese Ministry of Health and Welfare and the European
Union reporting requirements and under the reporting requirements of any other country as may be
applicable. Before submitting a report involving a Product either Party shall use its best efforts
to notify the other Party and to obtain any information it may have relating to any incident
involving a Product. Copies of such reports shall be sent to the other Party without delay. If
JMHW or any governmental authorities require to take any product corrective action (including
notification, recall, removal and correction) involving a Product in Japan, NK shall use its best
efforts to notify CSC by email within 24 hours from the receipt of such information and CSC shall
be responsible to determine the conduction or non-conduction of the corrective action within a
commercially reasonable time and manner after the receipt of the information from NK. In case that
CSC decides to take any corrective action for any product in overseas which is substantially the
same as the Product specified herein, the Product sold or distributed by NK in Japan shall also to
be taken corrective action.

     If FDA or other regulatory authorities contact either Party to inquire about or investigate
the Products sold under this Agreement, the contacted Party, unless required to maintain
confidentiality by such authorities, shall inform the other Party immediately thereof. The Parties
shall co-operate closely to clear any regulatory issues or potential regulatory issues promptly.

 

[*]  Designates portions of this document that have been omitted pursuant to a request for confidential treatment filed separately with the Commission.

- 14 -

 

     Notice required by this section 13.4 and 13.5 shall be responsible for each party’s Quality
Assurance Department.

     The information required from NK in case of reporting incidents are including the following:

	 	i)	 	identification of the device including brand name,
	 
	 	ii)	 	description of the incidents,
	 
	 	iii)	 	how the Product was involved and/or contributed to the incident,
	 
	 	iv)	 	identity of the person(s) who were affected by the incidents,
	 
	 	v)	 	identity of the medical personnel who were involved in the incident,
	 
	 	vi)	 	whether a death or serious injury occurred,
	 
	 	vii)	 	identity by name, address, telephone number, email and title of the person submitting
the information to the other Party,
	 
	 	viii)	 	whether the incidents have already been reported to the FDA or other authorities by
the person making the report

     13.6 In the event CSC decides to take any product corrective action in Japan (including
notification, recall, removal and correction) with respect to the Product sold or distributed by
NK, regardless of whether such action is initiated to comply with applicable laws or regulations or
for other reasons, the Parties agrees that: a) NK shall be the point of contact for purchasers of
its Products (whether directly of through its distributors); b) after discussion between the
parties, CSC will “define the action to be taken” and c) during the course of recall of the
Product, CSC shall work with NK to provide replacement Product if required by end user customers to
minimize any downtime of replacement Product. In such cases, CSC shall provide NK with efficient
quantity of replacement Product as soon as possible for NK’s immediate action to end user
customers, and CSC shall reimburse NK for direct costs of the type set forth below which are in
incurred by NK to implement such actions,

As used herein, “define action to be taken” means;

	 	i)	 	In the event of any recall of any Product, CSC shall work with NK to provide
investigation of scope and root cause of the Product failure, and provide a corrective
action plan for any found cause of the Product failure.
	 
	 	ii)	 	Defining the effectiveness check procedure (to establish the corrective action has been
completed).

 

[*]  Designates portions of this document that have been omitted pursuant to a request for confidential treatment filed separately with the Commission.

- 15 -

 

	 	iii)	 	CSC shall make every effort to pursue any necessary actions against the Vendor or
Supplier responsible for the Product.
	 
	 	iv)	 	If NK submits a corrective action request that accompanies a end user customer returned
Product that requires immediate response, then Seller shall respond with scope of problem
evidence of registration and initial plan for root cause analysis within 72 hours of the
request.

The type of costs reimbursable under this Section  13.6 are: mailing, telephone, telefax and
printing charges for shipment of the Product to NK back to CSC; and direct labor costs to
receive and handle returned Product and to replace the Product to end user customers. In case
that it is necessary for NK to confirm that Product is manufactured under appropriate
manufacturing and quality control, NK has a right to audit such system.

14. INTELLECTUAL PROPERTY RIGHTS

     14.1 Ownership. Except as expressly provided herein, neither Party grants to the
other Party any license or intellectual property right, whether by implication, estoppel or
otherwise in and to its Products, patents, trademarks, documentation and confidential information.
Except in the case of NK’s need to provide authorized service to said Products, NK shall not: (a)
reverse engineer, decompile, disassemble or otherwise tamper with the Products; (b) install,
integrate, adapt or use the Products except as described in CSC’s documentation; and (c) permit any
third party including any of NK’s distributors or end user customers to do any of the foregoing.

     14.2 CSC Trademarks. Subject to NK’s compliance with the terms of this Agreement,
CSC grants to NK the non-transferable and non-assignable right to use the trademarks, service
marks, trade names, logos or other words or symbols of CSC identifying the Products (the
Trademarks”) on NK’s advertising and promotional materials, stationery, signs, labels and packaging
in order to convey that NK is manufacturing Products, equipment or devices which incorporate the
Products. The Trademarks are and shall remain the exclusive property of CSC, whether or not such
ownership is specifically recognized or protected under the laws of the Territory. NK shall
acquire no rights to the Trademarks other than those set forth in this Article, and NK hereby
assigns and transfers to CSC all rights other than those granted pursuant to this Section that it
may acquire in and to the Trademarks, whether by operation of law or otherwise. NK shall comply
with CSC’s guidelines for the use of the Trademarks, and shall allow CSC an opportunity to inspect
the Products to confirm NK’s compliance herewith.

     14.3 NK Trademarks. CSC shall not use or refer to NK’s name or trademarks in any
other form or manner or for any other purpose than what is expressly allowed in this Agreement.
All artwork, packages and labels (if any) prepared by CSC in connection with the NK name shall be
sent to NK for approval.

 

[*]  Designates portions of this document that have been omitted pursuant to a request for confidential treatment filed separately with the Commission.

- 16 -

 

     14.4 Infringement. CSC warrants that it is the sole and exclusive owner of, or has
valid licenses, with the right to sublicense, the Products, in each case free and clear of any and
all liens, claims or encumbrances. CSC represents that (i) it has not been determined to be
infringing any patents or other rights with respect to the Products and (ii) no person has asserted
that CSC’s manufacture or sale of the Products anywhere in the world infringes any patent or other
proprietary right of such person.

     14.5 Notification. NK shall promptly notify CSC of (a) any claims, allegations or
notification that NK’s sale, offer to sell, license, lease, importation, export, transfer or
distribution of any Product may or will infringe the Intellectual Property Rights of a third party;
and (b) any determination, discovery, or notification that any person or entity is infringing or
may be infringing the Intellectual Property Rights of CSC.

     14.6 Alteration and Use. NK may not remove or alter any proprietary designs notices
or Marks contained in or on the Products, Documentation or related materials. NK may not make any
reference or claim about CSC or the Products or use any of CSC marks, which have not been approved
or provided by CSC.

15. CONFIDENTIALITY

     15.1 This Agreement and all documents, drawings, manuals and other materials related thereto
and transmitted between the Parties, provided that only if it is designated as “Confidential” in
writing when communicated, or within thirty (30) days of disclose, if disclosed orally, shall be
treated as confidential by the Parties and their employees and such information shall not be
disclosed to any third party. Without the other Party’s prior written consent, this Agreement and
any other materials treated as confidential hereunder may be disclosed by either parties in
compliance with governmental regulations and other corporate reporting requirements; provided that
such Party has notified the other Party and cooperated in good faith to take such steps as may be
reasonably available to protect the confidentiality of the information contained therein to the
extent requested by the other Party and as may be allowable by the applicable law. Confidential
Information does not include information that: a)at the time of disclosure is already known to the
public, b)becomes generally available to the public after disclosure through no fault on the party,
c)Recipient can demonstrate it had rightfully, prior to disclosure to Recipient by the other party,
d)Recipient rightfully obtains from a third party having the right to disclose it, or e) is
independently developed by recipient without the use of Confidential Information; Each Party shall
arrange proper filing for specifications and drawings given by the other Party. Each Party shall
nominate a person who shall be in charge of the filing and shall inform this person of the
confidentiality requirements of this Agreement. The parties agree to hold all Confidential
Information confidential for a period of two (2) years after the expiration and/or termination of
the Agreement.

 

[*]  Designates portions of this document that have been omitted pursuant to a request for confidential treatment filed separately with the Commission.

- 17 -

 

16. CSC INDEMNIFICATION

     16.1 Indemnity. Notwithstanding anything to the contrary contained herein and
subject to NK satisfying the conditions of Section 14, CSC shall indemnify and hold NK, its
affiliates and their respective directors, officers, employees and representatives harmless from
and against any suits, actions, losses, damages and other expenses solely arising out of or in
connection with any claim that any authorized use of a Product infringes or violates any
Intellectual Property Right or copyright of a third party.

     16.2 Remedies. If NK’s or any End-User’s use of the Products is prevented by an
injunction or court order because of any claim of infringement, CSC will, at its expense, and in
its sole discretion, use reasonable commercial efforts to: (a) replace or modify the Product, in
such a manner so as to maintain its functionality and compatibility, but nonetheless make the
Products, as applicable, no longer subject to a claim of infringement; or (b) procure for NK’s or
any End-User’s benefit the right to use and resell the Products, as applicable, as provided in this
Agreement. If (a) and (b) above are not commercially viable, CSC shall refund to NK all amounts
paid therefore by NK and shall terminate the rights granted herein.

     16.3 Exclusion. CSC will have no liability for any claim of indemnity if such claim
is based upon: (a) Products that have been modified, disassembled, reassembled, serviced, altered
or changed without the express written authorization of CSC; or (b) the combination, operation, or
use of the Products with software and/or hardware not supplied by CSC, if such liability would have
been avoided in the absence of such combination, operation or use.

     16.4 Entire Liability. This Article 16 states CSC’s entire liability for
infringement of any patent or other intellectual rights with respect to the Products

     16.5 Conditions. NK shall promptly notify CSC of (i) any matter for which NK may
claim indemnification, (ii) any claim against NK that any Products misappropriate any trade secret
or infringe any patent, copyright or other Intellectual Property Right of a third party and (iii)
any suit, action or proceeding brought against NK on the basis of any such claims. CSC shall, in
its sole discretion, defend or settle any such claim, suit, action or proceeding in any manner and
on any terms it shall deem appropriate, and the costs thereof (including any final award of
damages) shall be borne entirely by CSC. If CSC elects to defend any such suit, action or
proceeding, NK shall provide CSC, at CSC’s expense, with all the needed information, assistance and
authority necessary to enable CSC to defend such claim. NK shall not without CSC’s prior written
approval itself defend or settle any such suit, action or proceeding.

17. NK INDEMNITY

     17.1 General. Notwithstanding anything to the contrary contained herein, NK shall
indemnify and hold harmless CSC, its affiliates and their respective directors, officers,

 

[*]  Designates portions of this document that have been omitted pursuant to a request for confidential treatment filed separately with the Commission.

- 18 -

 

employees and representatives harmless from any claims, demands, actions, suits, proceedings,
judgments, damages, expenses and costs (including reasonable attorneys fees) related to:

          (a) Any of its activities under this Agreement, including any third party assertion that the
Products or any component thereof, to the extent they have been modified, disassembled,
reassembled, serviced, altered or changed by NK, infringe or misappropriate any patents or
copyrights of such third parties;

          (b) Death, injury or damage (including death) to any person or property caused by the
Products that have been subject to modification, alteration or change that NK instructed and/or
required to CSC.

     17.2 Conditions. CSC shall promptly notify NK of (i) any claim against CSC that
Products, which have been modified, disassembled, reassembled, serviced, altered or changed by NK
or CSC in accordance to NK’s instruction or requirement, misappropriate any trade secret or
infringe any patent, copyright or other intellectual property right of a third party and (ii) any
suit, action or proceeding brought against CSC on the basis of any such claims. NK shall, in its
sole discretion, defend or settle any such claim, suit, action or proceeding in any manner and on
any terms it shall deem appropriate, and the costs thereof (including any final award of damages)
shall be borne entirely by NK. If NK elects to defend any such suit, action or proceeding, CSC
shall provide NK, at NK’s expense, with all the needed information, assistance and authority
necessary to enable NK to defend such claim. CSC shall not without NK’s prior written approval
itself defend or settle any such suit, action or proceeding.

18. INSURANCE

     Throughout the term of this Agreement, and for a period of at least three (3) years
thereafter, CSC and NK shall each carry a reasonable amount of commercial general liability
insurance. Insurance is to be maintained by parties pursuant to the provisions of this Article and
shall provide for written notice to the other party thirty (30) days in advance of any termination
or cancellation of such insurance. Upon the request of either party from time to time during the
term hereof, each party shall provide the other with a certificate evidencing such insurance
coverage.

19. GENERAL

     19.1 Notices. All notices, requests, demands, waivers and other communications
required or permitted to be given under this Agreement are to be in writing and are deemed to be
duly given (a) upon being delivered either personally or by overnight courier with delivery charges
prepaid, (b) upon the fifth (5th) day from the date such notice was mailed by certified or
registered mail, postage prepaid, receipt requested, or (c) upon being sent by telecopy, to the
people and addresses set forth below or to such other person or address as either party may specify
by notice

 

[*]  Designates portions of this document that have been omitted pursuant to a request for confidential treatment filed separately with the Commission.

- 19 -

 

in writing to the other party. All notices, requests, demands, waivers and communications are
received on the date of delivery.

          If to CSC:

Cardiac Science Corporation.

3303 Monte Villa Parkway

Bothell, Washington 98021

Attention: John Hinson, President and Chief Executive Officer

Facsimile: (425) 402-2020

With a copy to:

Perkins Coie LLP

1201 Third Avenue, Suite 4800

Seattle, Washington 98101

Attention: Richard Rohde

Facsimile: (206) 359-7120

          If to NK:

Nihon Kohden Corporation

31-4 Nishiochiai 1 Chome

Shinjuku-ku, Tokyo 161-8560 JAPAN

Attention:

Facsimile:

     19.2 Force Majeure. If the performance of any obligation under this Agreement is
prevented, restricted or interfered with by reason of war, civil commotion, embargo, strike or any
other act which is beyond the reasonable control of the party affected, then the party so affected
shall, upon giving written notice to the other party, be excused from such performance to the
extent that such prevention, restriction or interference; provided that the party so affected shall
use commercially reasonably efforts to avoid and remove such causes of non-performance, and shall
continue performance hereunder with reasonable dispatch whenever such causes are removed.

     19.3 Successors and Assigns. This Agreement inures to the benefit of and is binding
upon the parties hereto and their successors and permitted assigns. Nothing in this Agreement,
expressed or implied, confers on any person other than the parties hereto (or their successors and
permitted assigns), any rights, remedies, obligations or liabilities.

 

[*]  Designates portions of this document that have been omitted pursuant to a request for confidential treatment filed separately with the Commission.

- 20 -

 

     19.4 Entire Agreement. This Agreement (including the Exhibits) is the entire
agreement between the parties hereto with respect to the subject matter hereof and supersedes all
other prior and contemporaneous agreements and understandings, oral and written.

     19.5 Assignment. Neither party may assign this Agreement without the prior written
approval of the other party.

     19.6 Relations. This Agreement creates no partnership, joint venture, franchise or
agency between the parties. Except as expressly set forth in this Agreement, neither party has the
right to assume or create, either directly or indirectly, any liability or any obligation of any
kind, expressed or implied, in the name of or on behalf of the other party, and neither party shall
represent that it has such authority.

     19.7 Waiver. This Agreement may only be waived or amended, if such waiver or
amendment is in writing, specifically references this Agreement and is executed by the party to be
bound. The waiver by either party of a breach of any provision of this Agreement does not operate
as a waiver of any other breach. A party’s failure or delay to exercise any right hereunder does
not operate as a waiver.

     19.8 Unenforceability. The illegality, invalidity or unenforceability of any part of
this Agreement does not affect the legality, validity or enforceability of the remainder of this
Agreement. If any part of this Agreement is found to be illegal, invalid or unenforceable, this
Agreement will be given such meaning as would make this Agreement legal, valid, and enforceable in
order to give effect to the intent of the parties.

     19.9 Governing Law. This Agreement is governed and construed according to the laws
of Washington, U.S.A. The court of competent jurisdiction shall be exclusively the district court
of Washington located in King County, Washington, U.S.A. if an action is brought by NK, or shall be
exclusively Tokyo district court, Japan if an action is brought by CSC.

     19.10 Dispute Resolution. Prior to taking any legal action, the parties shall
attempt to resolve any claim or controversy arising out of this Agreement by way of amicable
negotiations within a reasonable period not to exceed thirty (30) days after the date of a notice
from either party to the other describing such claim or controversy.

     19.11 Irreparable Harm. CSC and NK acknowledges that, in view of the uniqueness of
the transactions contemplated by this Agreement, a material breach or material failure to comply
with its confidentiality obligations or license restrictions would cause irreparable harm to other
party’s business and that the other party would not have an adequate remedy at law for money
damages. Therefore, CSC and NK agrees that NK and CSC is entitled to specific performance and/or
injunctive relief without the posting of bond or other security in addition to any other remedy to
which it may be entitled hereunder or at law or in equity, in any court of competent jurisdiction
against any such breach or noncompliance. All remedies provided for herein are

 

[*]  Designates portions of this document that have been omitted pursuant to a request for confidential treatment filed separately with the Commission.

- 21 -

 

cumulative and the exercise of any particular remedy by NK and CSC and does not limit or
preclude the exercise of any other remedy available to it.

     19.12 Survival. Articles and Sections 1, 2.2, 3.2, 3.3, 4.3, 5.5, 5.7, 5.9, 7.5, 9,
10.1, 11, 12, 13, 14, 15, 16 and 17 survive any expiration or termination of this Agreement.

     19.13 Counterparts. This Agreement may be executed in counterparts, each of which
shall be deemed an original and all of which together shall be deemed to be one and the same
instrument.

     19.14 Relation to the Prior Agreement. This Agreement applies to purchase and sale of
Products during the term of this Agreement set forth in Section 3 of this Agreement. The purchase
and sale of Products during the term of the Prior Agreement as set forth in Section 3 thereof shall
be governed by the terms of the Prior Agreement.

* * *

     IN WITNESS WHEREOF, the Parties have caused this OEM Supply and Purchase Agreement to be executed
by their duly authorized representatives.

	 	 	 
	Nihon Kohden Corporation

	 	Cardiac Science Corporation
	 
	 	 
	 

	 	 
	Name:

	 	Name: Allan Criss
	 
	 	 
	Title:

	 	Title: Senior Vice President of Sales and
Marketing

APPENDICES:

1. The Products

 

[*]  Designates portions of this document that have been omitted pursuant to a request for confidential treatment filed separately with the Commission.

- 22 -

 

2. Prices

3. Technical Specifications

4. Definitions

5. Notification of Quality Control and Assurance from CSC

 
 

[*]  Designates portions of this document that have been omitted pursuant to a request for confidential treatment filed separately with the Commission.

- 23 -

 

APPENDIX 1

The Products

          The Products consist of the following:

          A.I. The AED 9231 is a portable automated external defibrillator that analyzes a persons’
electrocardiogram and advises an operator to deliver an electric shock(s) using monophasic or
biphasic defibrillation technology to a patient in order to restore normal heart rhythm; and
includes Cardiac Science’s patented RescueReady technology such as one button operation,
pre-connected disposable electrode pads and status indicator. The AED 9231s ordered by NK under
this Agreement will have NK specified coloring and labeling as agreed upon by the Parties

          A.2. The “Electrodes” or “Replacement Electrodes” are single patient use defibrillation
electrodes for use with the AED 9231s. Electrodes ordered by NK under this Agreement will be
labeled under the NK tradename and packaged in such as way to accommodate the RescueReady
capabilities of the AED 9231.

          Technical specifications of the Products are attached hereto as Appendix 3.

          Products include only versions that have been commercially released by CSC, and NK shall not
sell or distribute any pre-released versions provided by CSC for test, evaluation, demonstration,
promotional or other purposes.

          If CSC commercially releases a successor to the AED 9231 during the Term (“Successor
Product”), then CSC shall make the Successor Product available for purchase by NK under this
Agreement; provided that the Parties agree upon pricing and minimum quantity commitments by NK for
the Successor Product. In such event, the Parties shall amend this Appendix 1 and Appendix 2 to
include the Successor Product. For purposes of foregoing, the Successor Product is limited to the
next released portable automated external defibrillator that has a feature set equivalent to or
higher than the feature set in the version of the AED 9231 offered by CSC on the Effective Date and
that is intended to replace the AED 9231 in the applicable market.

          Additional models and other devices, systems, components and/or parts may be added as
“Products” under this Agreement by mutual written agreement of the Parties.

 

[*]  Designates portions of this document that have been omitted pursuant to a request for confidential treatment filed separately with the Commission.

- 24 -

 

APPENDIX 2

The prices for the Products during the Term from the Effective Date to [*] are as follows (the
Target Number of Units is based upon the prices):

Prices for AED 9231 (without electrode pads)

	 	 	 	 	 
	Month	 	Target Number of Units	 	Price per Unit
	[*]

	 	[*]
	 	[*]
	[*]

	 	[*]
	 	[*]
	[*]

	 	[*]
	 	[*]
	Total

	 	[*]	 	 

	 	 	 	 	 
	Quarter	 	Target Number of Units	 	Price per Unit
	[*]

	 	[*]
	 	[*]
	[*]

	 	[*]
	 	[*]
	[*]

	 	[*]
	 	[*]
	[*]

	 	[*]
	 	[*]
	Total

	 	[*]	 	 

A potential additional purchase of up to [*]additional units
above the [*] forecasted or targeted above, at the price points
listed below. The [*] will be a one time only purchase in the
[*] time frame. The price for the additional number of units
is contingent on CSC receiving a purchase order for the [*]
units for [*] and the [*] units forecasted for [*], prior to
receiving an order for the additional [*] units.

	 	 	 	 	 
	Number of Units	 	Price per Unit	 	 
	1 to 1,000

	 	[*]	 	 
	1,001 to 2,000

	 	[*]	 	 
	2,001 and up

	 	[*]	 	 

 

[*]  Designates portions of this document that have been omitted pursuant to a request for confidential treatment filed separately with the Commission.

- 25 -

 

Prices

	 	 	 	 	 
	Product	 	 	 	Price, $USD
	NK branded AED 9231 Electrodes

	 	any quantity
	 	[*]
	 
	 	 	 	 
	Datacard Adapter

	 	any quantity
	 	[*]
	 
	 	 	 	 
	USB to RS-232 Plug in Adapter
All prices are in US Dollars (USD)

	 	any quantity
	 	[*]

 
 

[*]  Designates portions of this document that have been omitted pursuant to a request for confidential treatment filed separately with the Commission.

- 26 -

 

APPENDIX 3

Technical Specifications

[*]

 

[*]  Designates portions of this document that have been omitted pursuant to a request for confidential treatment filed separately with the Commission.

- 27 -

 

APPENDIX 4

Definitions

	 	1.	 	The following is a listing for convenient reference of terms as defined in this
Agreement:
	 
	 	2.	 	Affiliate means with respect to any specified party, any other legal entity that
directly or indirectly controls, is controlled by or is under common control with, such
specified party.
	 
	 	3.	 	CSC means Cardiac Science Corporation.
	 
	 	4.	 	NK means the Nihon Kohden Corporation.
	 
	 	5.	 	Effective Date means January 1, 2008.
	 
	 	6.	 	Replacement Electrode and Electrode mean the electrodes specified in Appendix 1.
	 
	 	7.	 	MDD means the counsel directive 93/42 EEC concerning medical devices promulgated by the
Council of the European Communities as amended.
	 
	 	8.	 	Module means the module specified in Appendix 1.
	 
	 	9.	 	Party or Parties means NK and CSC individually and collectively as applicable.
	 
	 	10.	 	Products means the products specified in Appendix 1.
	 
	 	11.	 	U.S. GMP means the requirements of U.S. GMP 21 CFR 820.

 

[*]  Designates portions of this document that have been omitted pursuant to a request for confidential treatment filed separately with the Commission.

- 28 -

 

Appendix 5

Notification of Quality Control and Assurance from CSC

	1.	 	CSC shall inform the following of NK in writing.
	 
	 	 	CSC shall inform NK of attentions which NK shall inform to purchaser or installer of products,
if there are some possibilities that product is installed in non-medical institution and
operated by personnel who are not qualified as a doctor or not trained.
	 
	 	 	CSC shall inform NK of the contents of the obligation of purchaser or installer concerning
control or maintenance of products. CSC shall inform NK of the contents of the obligation of NK
concerning control or maintenance of installed products.
	 
	2.	 	In the following cases, CSC shall inform NK in writing immediately (within at least 1 week).
	 
	 	 	After the products are supplied to the customer, if there are any mistakes or omissions which
shall be corrected, or if there are any other additional items concerning safety which are not
described on the operator’s manual, CSC shall inform NK of them in writing.
	 
	3.	 	In the following cases, CSC shall inform NK by fax quickly.
	 
	 	 	CSC shall inform NK by fax, if any adverse events concerning AED 9231 are reported in a medical
congress, in Enforcement Report or MDR by FDA. The information of any adverse events includes
the product of other company. CSC shall not be obligated to notify NK of routine submission of
MDRs to the FDA or routine product complaints.
	 
	 	 	CSC shall inform NK by fax if the failure or the claim concerning safety of products of CSC has
occurred, regardless of whether CSC has the responsibility or not, or whether the product is
failure or not.
	 
	 	 	CSC shall inform NK by fax if software is changed.
	 
	 	 	Where automatic charge and/or internal discharge algorithm or arrhythmia detection algorithm is
changed, or change that affects input and output or the result of arrhythmia detection program
is implemented, CSC shall inform NK of the differences between changed products and previous
products, the purpose or reason of the change, and identify the scope of the change (whether it
is applied to products which has already supplied to the customer, or it limits products which
will be shipped in the future) and explain the reason to NK.
	 
	4.	 	When the circuit or material or structure of the products is improved or changed, CSC shall
inform NK of the outline and serial number, regardless of the details of notification to JMHW.
In the following cases, CSC shall inform NK of them in written quickly.

 

[*]  Designates portions of this document that have been omitted pursuant to a request for confidential treatment filed separately with the Commission.

- 29 -

 

	1)	 	When parts, related to electrical isolation of applied part from live parts, and creepage
distance, air clearance and construction related to dielectric stress are changed, or these
parts manufacturers are changed.
	 
	2)	 	When exterior material of the products is changed.
	 
	3)	 	When dimension and weight are changed more than +/- 5% greater.
	 
	4)	 	When specification affects the products’ performance, quality and function.
	 
	5)	 	When block diagram is changed.
	 
	6)	 	When testing procedure is changed.

 

[*]  Designates portions of this document that have been omitted pursuant to a request for confidential treatment filed separately with the Commission.

- 30 -exv10w5

 

Exhibit 10.5

 

 

 

    infoGROUP
    INC.

    

 

    AMENDED
    AND RESTATED 2007 OMNIBUS INCENTIVE PLAN

 

 

 

 

    TABLE OF
    CONTENTS

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
    Page
	
 

	 

	
 
	
    1.
	
 
	
 
	
    PURPOSE
	
 
	
 
	
    A-1
	
 

	
 
	
    2.
	
 
	
 
	
    DEFINITIONS
	
 
	
 
	
    A-1
	
 

	
 
	
    3.
	
 
	
 
	
    ADMINISTRATION OF THE PLAN
	
 
	
 
	
    A-3
	
 

	
 
	
 
	
 
	
 
	
 
	
    3.1.
	
 
	
 
	
    Board
	
 
	
 
	
    A-3
	
 

	
 
	
 
	
 
	
 
	
 
	
    3.2.
	
 
	
 
	
    Committee
	
 
	
 
	
    A-4
	
 

	
 
	
 
	
 
	
 
	
 
	
    3.3.
	
 
	
 
	
    Terms of Awards
	
 
	
 
	
    A-4
	
 

	
 
	
 
	
 
	
 
	
 
	
    3.4.
	
 
	
 
	
    Deferral Arrangement
	
 
	
 
	
    A-5
	
 

	
 
	
 
	
 
	
 
	
 
	
    3.5.
	
 
	
 
	
    No Liability
	
 
	
 
	
    A-5
	
 

	
 
	
 
	
 
	
 
	
 
	
    3.6.
	
 
	
 
	
    Share Issuance/Book-Entry
	
 
	
 
	
    A-5
	
 

	
 
	
    4.
	
 
	
 
	
    STOCK SUBJECT TO THE PLAN
	
 
	
 
	
    A-5
	
 

	
 
	
    5.
	
 
	
 
	
    EFFECTIVE DATE, DURATION AND AMENDMENTS
	
 
	
 
	
    A-5
	
 

	
 
	
 
	
 
	
 
	
 
	
    5.1.
	
 
	
 
	
    Effective Date
	
 
	
 
	
    A-5
	
 

	
 
	
 
	
 
	
 
	
 
	
    5.2.
	
 
	
 
	
    Term
	
 
	
 
	
    A-5
	
 

	
 
	
 
	
 
	
 
	
 
	
    5.3.
	
 
	
 
	
    Amendment and Termination of the Plan
	
 
	
 
	
    A-6
	
 

	
 
	
    6.
	
 
	
 
	
    AWARD ELIGIBILITY AND LIMITATIONS
	
 
	
 
	
    A-6
	
 

	
 
	
 
	
 
	
 
	
 
	
    6.1.
	
 
	
 
	
    Service Providers and Other Persons
	
 
	
 
	
    A-6
	
 

	
 
	
 
	
 
	
 
	
 
	
    6.2.
	
 
	
 
	
    Successive Awards and Substitute Awards
	
 
	
 
	
    A-6
	
 

	
 
	
 
	
 
	
 
	
 
	
    6.3.
	
 
	
 
	
    Limitation on Shares of Stock Subject to Awards and Cash Awards
	
 
	
 
	
    A-6
	
 

	
 
	
    7.
	
 
	
 
	
    AWARD AGREEMENT
	
 
	
 
	
    A-6
	
 

	
 
	
    8.
	
 
	
 
	
    TERMS AND CONDITIONS OF OPTIONS
	
 
	
 
	
    A-6
	
 

	
 
	
 
	
 
	
 
	
 
	
    8.1.
	
 
	
 
	
    Option Price
	
 
	
 
	
    A-6
	
 

	
 
	
 
	
 
	
 
	
 
	
    8.2.
	
 
	
 
	
    Vesting
	
 
	
 
	
    A-7
	
 

	
 
	
 
	
 
	
 
	
 
	
    8.3.
	
 
	
 
	
    Term
	
 
	
 
	
    A-7
	
 

	
 
	
 
	
 
	
 
	
 
	
    8.4.
	
 
	
 
	
    Termination of Service
	
 
	
 
	
    A-7
	
 

	
 
	
 
	
 
	
 
	
 
	
    8.5.
	
 
	
 
	
    Limitations on Exercise of Option
	
 
	
 
	
    A-7
	
 

	
 
	
 
	
 
	
 
	
 
	
    8.6.
	
 
	
 
	
    Method of Exercise
	
 
	
 
	
    A-7
	
 

	
 
	
 
	
 
	
 
	
 
	
    8.7.
	
 
	
 
	
    Rights of Holders of Options
	
 
	
 
	
    A-7
	
 

	
 
	
 
	
 
	
 
	
 
	
    8.8.
	
 
	
 
	
    Delivery of Stock Certificates
	
 
	
 
	
    A-7
	
 

	
 
	
 
	
 
	
 
	
 
	
    8.9.
	
 
	
 
	
    Transferability of Options
	
 
	
 
	
    A-8
	
 

	
 
	
 
	
 
	
 
	
 
	
    8.10.
	
 
	
 
	
    Family Transfers
	
 
	
 
	
    A-8
	
 

	
 
	
 
	
 
	
 
	
 
	
    8.11.
	
 
	
 
	
    Limitations on Incentive Stock Options
	
 
	
 
	
    A-8
	
 

	
 
	
    9.
	
 
	
 
	
    TERMS AND CONDITIONS OF STOCK APPRECIATION RIGHTS
	
 
	
 
	
    A-8
	
 

	
 
	
 
	
 
	
 
	
 
	
    9.1.
	
 
	
 
	
    Right to Payment and Grant Price
	
 
	
 
	
    A-8
	
 

	
 
	
 
	
 
	
 
	
 
	
    9.2.
	
 
	
 
	
    Other Terms
	
 
	
 
	
    A-8
	
 

	
 
	
 
	
 
	
 
	
 
	
    9.3.
	
 
	
 
	
    Term
	
 
	
 
	
    A-8
	
 

	
 
	
 
	
 
	
 
	
 
	
    9.4.
	
 
	
 
	
    Transferability of SARS
	
 
	
 
	
    A-9
	
 

	
 
	
 
	
 
	
 
	
 
	
    9.5.
	
 
	
 
	
    Family Transfers
	
 
	
 
	
    A-9
	
 

	
 
	
    10.
	
 
	
 
	
    TERMS AND CONDITIONS OF RESTRICTED STOCK AND STOCK UNITS
	
 
	
 
	
    A-9
	
 

	
 
	
 
	
 
	
 
	
 
	
    10.1.
	
 
	
 
	
    Grant of Restricted Stock or Stock Units
	
 
	
 
	
    A-9
	
 

	
 
	
 
	
 
	
 
	
 
	
    10.2.
	
 
	
 
	
    Restrictions
	
 
	
 
	
    A-9
	
 

	
 
	
 
	
 
	
 
	
 
	
    10.3.
	
 
	
 
	
    Restricted Stock Certificates
	
 
	
 
	
    A-9
	
 

	
 
	
 
	
 
	
 
	
 
	
    10.4.
	
 
	
 
	
    Rights of Holders of Restricted Stock
	
 
	
 
	
    A-9
	
 

    A-i

 

	 	 	 	 	 	 	 	 	 	 	 	 	 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
    Page
	
 

	 

	
 
	
 
	
 
	
 
	
 
	
    10.5.
	
 
	
 
	
    Rights of Holders of Stock Units
	
 
	
 
	
    A-10
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
    10.5.1. Voting and Dividend Rights
	
 
	
 
	
    A-10
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
    10.5.2. Creditor’s Rights
	
 
	
 
	
    A-10
	
 

	
 
	
 
	
 
	
 
	
 
	
    10.6.
	
 
	
 
	
    Termination of Service
	
 
	
 
	
    A-10
	
 

	
 
	
 
	
 
	
 
	
 
	
    10.7.
	
 
	
 
	
    Purchase of Restricted Stock
	
 
	
 
	
    A-10
	
 

	
 
	
 
	
 
	
 
	
 
	
    10.8.
	
 
	
 
	
    Delivery of Stock
	
 
	
 
	
    A-10
	
 

	
 
	
    11.
	
 
	
 
	
    TERMS AND CONDITIONS OF UNRESTRICTED STOCK AWARDS
	
 
	
 
	
    A-10
	
 

	
 
	
    12.
	
 
	
 
	
    FORM OF PAYMENT FOR OPTIONS AND RESTRICTED STOCK
	
 
	
 
	
    A-10
	
 

	
 
	
 
	
 
	
 
	
 
	
    12.1.
	
 
	
 
	
    General Rule
	
 
	
 
	
    A-10
	
 

	
 
	
 
	
 
	
 
	
 
	
    12.2.
	
 
	
 
	
    Surrender of Stock
	
 
	
 
	
    A-11
	
 

	
 
	
 
	
 
	
 
	
 
	
    12.3.
	
 
	
 
	
    Cashless Exercise
	
 
	
 
	
    A-11
	
 

	
 
	
 
	
 
	
 
	
 
	
    12.4.
	
 
	
 
	
    Other Forms of Payment
	
 
	
 
	
    A-11
	
 

	
 
	
    13.
	
 
	
 
	
    TERMS AND CONDITIONS OF DIVIDEND EQUIVALENT RIGHTS
	
 
	
 
	
    A-11
	
 

	
 
	
 
	
 
	
 
	
 
	
    13.1.
	
 
	
 
	
    Dividend Equivalent Rights
	
 
	
 
	
    A-11
	
 

	
 
	
 
	
 
	
 
	
 
	
    13.2.
	
 
	
 
	
    Termination of Service
	
 
	
 
	
    A-11
	
 

	
 
	
    14.
	
 
	
 
	
    TERMS AND CONDITIONS OF PERFORMANCE AND ANNUAL INCENTIVE AWARDS
	
 
	
 
	
    A-11
	
 

	
 
	
 
	
 
	
 
	
 
	
    14.1.
	
 
	
 
	
    Performance Conditions
	
 
	
 
	
    A-11
	
 

	
 
	
 
	
 
	
 
	
 
	
    14.2.
	
 
	
 
	
    Performance or Annual Incentive Awards Granted to Designated
    Covered Employees
	
 
	
 
	
    A-12
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
    14.2.1. Performance Goals Generally
	
 
	
 
	
    A-12
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
    14.2.2. Business Criteria
	
 
	
 
	
    A-12
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
    14.2.3. Timing For Establishing Performance Goals
	
 
	
 
	
    A-12
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
    14.2.4. Settlement of Performance or Annual Incentive Awards;
    Other Terms
	
 
	
 
	
    A-12
	
 

	
 
	
 
	
 
	
 
	
 
	
    14.3.
	
 
	
 
	
    Written Determinations
	
 
	
 
	
    A-13
	
 

	
 
	
 
	
 
	
 
	
 
	
    14.4.
	
 
	
 
	
    Status of Section 14.2 Awards Under Code Section 162(m)
	
 
	
 
	
    A-13
	
 

	
 
	
    15.
	
 
	
 
	
    PARACHUTE LIMITATIONS
	
 
	
 
	
    A-13
	
 

	
 
	
    16.
	
 
	
 
	
    REQUIREMENTS OF LAW
	
 
	
 
	
    A-14
	
 

	
 
	
 
	
 
	
 
	
 
	
    16.1.
	
 
	
 
	
    General
	
 
	
 
	
    A-14
	
 

	
 
	
 
	
 
	
 
	
 
	
    16.2.
	
 
	
 
	
    Rule 16b-3
	
 
	
 
	
    A-14
	
 

	
 
	
    17.
	
 
	
 
	
    EFFECT OF CHANGES IN CAPITALIZATION
	
 
	
 
	
    A-14
	
 

	
 
	
 
	
 
	
 
	
 
	
    17.1.
	
 
	
 
	
    Changes in Stock
	
 
	
 
	
    A-14
	
 

	
 
	
 
	
 
	
 
	
 
	
    17.2.
	
 
	
 
	
    Reorganization in Which the Company Is the Surviving Entity
    Which does not Constitute a Corporate Transaction
	
 
	
 
	
    

    A-15
	
 

	
 
	
 
	
 
	
 
	
 
	
    17.3.
	
 
	
 
	
    Corporate Transaction
	
 
	
 
	
    A-15
	
 

	
 
	
 
	
 
	
 
	
 
	
    17.4.
	
 
	
 
	
    Adjustments
	
 
	
 
	
    A-16
	
 

	
 
	
 
	
 
	
 
	
 
	
    17.5.
	
 
	
 
	
    No Limitations on Company
	
 
	
 
	
    A-16
	
 

	
 
	
    18.
	
 
	
 
	
    GENERAL PROVISIONS
	
 
	
 
	
    A-16
	
 

	
 
	
 
	
 
	
 
	
 
	
    18.1.
	
 
	
 
	
    Disclaimer of Rights
	
 
	
 
	
    A-16
	
 

	
 
	
 
	
 
	
 
	
 
	
    18.2.
	
 
	
 
	
    Nonexclusivity of the Plan
	
 
	
 
	
    A-16
	
 

	
 
	
 
	
 
	
 
	
 
	
    18.3.
	
 
	
 
	
    Withholding Taxes
	
 
	
 
	
    A-16
	
 

	
 
	
 
	
 
	
 
	
 
	
    18.4.
	
 
	
 
	
    Captions
	
 
	
 
	
    A-17
	
 

	
 
	
 
	
 
	
 
	
 
	
    18.5.
	
 
	
 
	
    Other Provisions
	
 
	
 
	
    A-17
	
 

	
 
	
 
	
 
	
 
	
 
	
    18.6.
	
 
	
 
	
    Number and Gender
	
 
	
 
	
    A-17
	
 

	
 
	
 
	
 
	
 
	
 
	
    18.7.
	
 
	
 
	
    Severability
	
 
	
 
	
    A-17
	
 

	
 
	
 
	
 
	
 
	
 
	
    18.8.
	
 
	
 
	
    Governing Law
	
 
	
 
	
    A-17
	
 

	
 
	
 
	
 
	
 
	
 
	
    18.9.
	
 
	
 
	
    Section 409A of the Code
	
 
	
 
	
    A-17
	
 

    A-ii

 

    infoGROUP
    INC.

    

 

    AMENDED
    AND RESTATED 2007 OMNIBUS INCENTIVE PLAN

 

    infoGROUP Inc., a Delaware corporation (the
    “Company”), sets forth herein the terms of its Amended
    and Restated 2007 Omnibus Incentive Plan (the “Plan”),
    as follows:

 

		
	
    1.  
	
    PURPOSE

 

    The Plan is intended to enhance the Company’s and its
    Affiliates’ (as defined herein) ability to attract and
    retain highly qualified officers, directors, key employees, and
    other persons, and to motivate such persons to serve the Company
    and its Affiliates and to expend maximum effort to improve the
    business results and earnings of the Company, by providing to
    such persons an opportunity to acquire or increase a direct
    proprietary interest in the operations and future success of the
    Company. To this end, the Plan provides for the grant of stock
    options, stock appreciation rights, restricted stock, stock
    units, unrestricted stock, dividend equivalent rights and cash
    awards. Any of these awards may, but need not, be made as
    performance incentives to reward attainment of annual or
    long-term performance goals in accordance with the terms hereof.
    Stock options granted under the Plan may be non-qualified stock
    options or incentive stock options, as provided herein.

 

		
	
    2.  
	
    DEFINITIONS

 

    For purposes of interpreting the Plan and related documents
    (including Award Agreements), the following definitions shall
    apply:

 

    2.1  “Affiliate” means, with respect
    to the Company, any company or other trade or business that
    controls, is controlled by or is under common control with the
    Company within the meaning of Rule 405 of Regulation C
    under the Securities Act, including, without limitation, any
    Subsidiary.

 

    2.2  “Annual Incentive Award” means
    an Award made subject to attainment of performance goals (as
    described in Section 14) over a performance period
    of up to one year (the Company’s fiscal year, unless
    otherwise specified by the Committee).

 

    2.3  “Award” means a grant of an
    Option, Stock Appreciation Right, Restricted Stock, Unrestricted
    Stock, Stock Unit, Dividend Equivalent Rights, or cash award
    under the Plan.

 

    2.4  “Award Agreement” means the
    written agreement between the Company and a Grantee that
    evidences and sets out the terms and conditions of an Award.

 

    2.5  “Benefit Arrangement” shall have
    the meaning set forth in Section 15 hereof.

 

    2.6  “Board” means the Board of
    Directors of the Company.

 

    2.7  “Cause” means, as determined by
    the Board and unless otherwise provided in an applicable
    agreement with the Company or an Affiliate, (i) gross
    negligence or willful misconduct in connection with the
    performance of duties; (ii) conviction of a criminal
    offense (other than minor traffic offenses); or
    (iii) material breach of any term of any employment,
    consulting or other services, confidentiality, intellectual
    property or non-competition agreements, if any, between the
    Service Provider and the Company or an Affiliate.

 

    2.8  “Code” means the Internal
    Revenue Code of 1986, as now in effect or as hereafter amended.

 

    2.9  “Committee” means a committee
    of, and designated from time to time by resolution of, the
    Board, which shall be constituted as provided in
    Section 3.2.

 

    2.10  “Company” means infoGROUP Inc.

 

    2.11  “Corporate Transaction” means
    (i) the dissolution or liquidation of the Company or a
    merger, consolidation, or reorganization of the Company with one
    or more other entities in which the Company is not the surviving
    entity, (ii) a sale of substantially all of the assets of
    the Company to another person or entity, or (iii) any
    transaction (including without limitation a merger or
    reorganization in which the Company is the surviving entity)

    

    A-1

 

    which results in any person or entity (other than persons who
    are stockholders or Affiliates immediately prior to the
    transaction) owning 50% or more of the combined voting power of
    all classes of stock of the Company.

 

    2.12  “Covered Employee” means a
    Grantee who is a covered employee within the meaning of
    Section 162(m)(3) of the Code.

 

    2.13  “Disability” means the Grantee
    is unable to perform each of the essential duties of such
    Grantee’s position by reason of a medically determinable
    physical or mental impairment which is potentially permanent in
    character or which can be expected to last for a continuous
    period of not less than 12 months; provided, however, that,
    with respect to rules regarding expiration of an Incentive Stock
    Option following termination of the Grantee’s Service,
    Disability shall mean the Grantee is unable to engage in any
    substantial gainful activity by reason of a medically
    determinable physical or mental impairment which can be expected
    to result in death or which has lasted or can be expected to
    last for a continuous period of not less than 12 months.

 

    2.14  “Dividend Equivalent Right”
    means a right, granted to a Grantee under Section 13
    hereof, to receive cash, Stock, other Awards or other
    property equal in value to dividends paid with respect to a
    specified number of shares of Stock, or other periodic payments.

 

    2.15  “Effective Date” means
    October 23, 2008, the date the Plan is approved by the
    Company’s stockholders.

 

    2.16  “Exchange Act” means the
    Securities Exchange Act of 1934, as now in effect or as
    hereafter amended.

 

    2.17  “Fair Market Value” means the
    value of a share of Stock, determined as follows: if on the
    Grant Date or other determination date the Stock is listed on an
    established national or regional stock exchange, is admitted to
    quotation on The Nasdaq Stock Market, Inc. or is publicly traded
    on an established securities market, the Fair Market Value of a
    share of Stock shall be the closing price of the Stock on such
    exchange or in such market (if there is more than one such
    exchange or market the Board shall determine the appropriate
    exchange or market) on the Grant Date or such other
    determination date (or if there is no such reported closing
    price, the Fair Market Value shall be the mean between the
    highest bid and lowest asked prices or between the high and low
    sale prices on such trading day) or, if no sale of Stock is
    reported for such trading day, on the next preceding day on
    which any sale shall have been reported. If the Stock is not
    listed on such an exchange, quoted on such system or traded on
    such a market, Fair Market Value shall be the value of the Stock
    as determined by the Board in good faith in a manner consistent
    with Code Section 409A.

 

    2.18  “Family Member” means a person
    who is a spouse, former spouse, child, stepchild, grandchild,
    parent, stepparent, grandparent, niece, nephew,
    mother-in-law,
    father-in-law,
    son-in-law,
    daughter-in-law,
    brother, sister,
    brother-in-law,
    or
    sister-in-law,
    including adoptive relationships, of the Grantee, any person
    sharing the Grantee’s household (other than a tenant or
    employee), a trust in which any one or more of these persons
    have more than fifty percent of the beneficial interest, a
    foundation in which any one or more of these persons (or the
    Grantee) control the management of assets, and any other entity
    in which one or more of these persons (or the Grantee) own more
    than fifty percent of the voting interests.

 

    2.19  “Grant Date” means, as
    determined by the Board, the latest to occur of (i) the
    date as of which the Board approves an Award, (ii) the date
    on which the recipient of an Award first becomes eligible to
    receive an Award under Section 6 hereof, or
    (iii) such other date as may be specified by the Board.

 

    2.20  “Grantee” means a person who
    receives or holds an Award under the Plan.

 

    2.21  “Incentive Stock Option” means
    an “incentive stock option” within the meaning of
    Section 422 of the Code, or the corresponding provision of
    any subsequently enacted tax statute, as amended from time to
    time.

 

    2.22  “Non-qualified Stock Option”
    means an Option that is not an Incentive Stock Option.

 

    2.23  “Option” means an option to
    purchase one or more shares of Stock pursuant to the Plan.

 

    2.24  “Option Price” means the
    exercise price for each share of Stock subject to an Option.

 

    2.25  “Other Agreement” shall have
    the meaning set forth in Section 15 hereof.

    

    A-2

 

    2.26  “Outside Director” means a
    member of the Board who is not an officer or employee of the
    Company.

 

    2.27  “Performance Award” means an
    Award made subject to the attainment of performance goals (as
    described in Section 14) over a performance period
    of up to ten (10) years.

 

    2.28  “Plan” means this
    infoGROUP Inc. Amended and Restated 2007 Omnibus
    Incentive Plan.

 

    2.29  “Purchase Price” means the
    purchase price for each share of Stock pursuant to a grant of
    Restricted Stock or Unrestricted Stock.

 

    2.30  “Reporting Person” means a
    person who is required to file reports under Section 16(a)
    of the Exchange Act.

 

    2.31  “Restricted Stock” means shares
    of Stock, awarded to a Grantee pursuant to Section 10
    hereof.

 

    2.32  “SAR Exercise Price” means the
    per share exercise price of an SAR granted to a Grantee under
    Section 9 hereof.

 

    2.33  “Securities Act” means the
    Securities Act of 1933, as now in effect or as hereafter amended.

 

    2.34  “Service” means service as a
    Service Provider to the Company or an Affiliate. Unless
    otherwise stated in the applicable Award Agreement, a
    Grantee’s change in position or duties shall not result in
    interrupted or terminated Service, so long as such Grantee
    continues to be a Service Provider to the Company or an
    Affiliate. Subject to the preceding sentence, whether a
    termination of Service shall have occurred for purposes of the
    Plan shall be determined by the Board, which determination shall
    be final, binding and conclusive.

 

    2.35  “Service Provider” means an
    employee, officer or director of the Company or an Affiliate, or
    a consultant or adviser currently providing services to the
    Company or an Affiliate.

 

    2.36  “Stock” means the common stock,
    par value $.0025 per share, of the Company.

 

    2.37  “Stock Appreciation Right” or
    “SAR” means a right granted to a Grantee under
    Section 9 hereof.

 

    2.38  “Stock Unit” means a
    bookkeeping entry representing the equivalent of one share of
    Stock awarded to a Grantee pursuant to Section 10
    hereof.

 

    2.39  “Subsidiary” means any
    “subsidiary corporation” of the Company within the
    meaning of Section 424(f) of the Code.

 

    2.40  “Substitute Awards” means
    Awards granted upon assumption of, or in substitution for,
    outstanding awards previously granted by a company or other
    entity acquired by the Company or any Affiliate or with which
    the Company or any Affiliate combines.

 

    2.41  “Ten Percent Stockholder”
    means an individual who owns more than ten percent (10%) of
    the total combined voting power of all classes of outstanding
    stock of the Company, its parent or any of its Subsidiaries. In
    determining stock ownership, the attribution rules of
    Section 424(d) of the Code shall be applied.

 

    2.42  “Unrestricted Stock” means an
    Award pursuant to Section 11 hereof.

 

		
	
    3.  
	
    ADMINISTRATION
    OF THE PLAN

 

    3.1.  Board.

 

    The Board shall have such powers and authorities related to the
    administration of the Plan as are consistent with the
    Company’s certificate of incorporation and by-laws and
    applicable law. The Board shall have full power and authority to
    take all actions and to make all determinations required or
    provided for under the Plan, any Award or any Award Agreement,
    and shall have full power and authority to take all such other
    actions and make all such other determinations not inconsistent
    with the specific terms and provisions of the Plan that the
    Board deems to be necessary or appropriate to the administration
    of the Plan, any Award or any Award Agreement. All such actions
    and determinations shall be by the affirmative vote of a
    majority of the members of the Board present at a meeting or by
    unanimous consent of the Board executed in writing in accordance
    with the Company’s certificate of incorporation

    

    A-3

 

    and by-laws and applicable law. The interpretation and
    construction by the Board of any provision of the Plan, any
    Award or any Award Agreement shall be final, binding and
    conclusive.

 

    3.2.  Committee.

 

    The Board from time to time may delegate to the Committee such
    powers and authorities related to the administration and
    implementation of the Plan, as set forth in Section 3.1
    above and other applicable provisions, as the Board shall
    determine, consistent with the certificate of incorporation and
    by-laws of the Company and applicable law.

 

    (i) Except as provided in Subsection (ii) and except
    as the Board may otherwise determine, the Committee, if any,
    appointed by the Board to administer the Plan shall consist of
    two or more Outside Directors of the Company who:
    (a) qualify as “outside directors” within the
    meaning of Section 162(m) of the Code and who (b) meet
    such other requirements as may be established from time to time
    by the Securities and Exchange Commission for plans intended to
    qualify for exemption under
    Rule 16b-3
    (or its successor) under the Exchange Act and who
    (c) comply with the independence requirements of the stock
    exchange on which the Common Stock is listed.

 

    (ii) The Board may also appoint one or more separate
    committees of the Board, each composed of one or more directors
    of the Company who need not be Outside Directors, who may
    administer the Plan with respect to employees or other Service
    Providers who are not officers or directors of the Company, may
    grant Awards under the Plan to such employees or other Service
    Providers, and may determine all terms of such Awards.

 

    In the event that the Plan, any Award or any Award Agreement
    entered into hereunder provides for any action to be taken by or
    determination to be made by the Board, such action may be taken
    or such determination may be made by the Committee if the power
    and authority to do so has been delegated to the Committee by
    the Board as provided for in this Section. Unless otherwise
    expressly determined by the Board, any such action or
    determination by the Committee shall be final, binding and
    conclusive. To the extent permitted by law, the Committee may
    delegate its authority under the Plan to a member of the Board.

 

    3.3.  Terms of Awards.

 

    Subject to the other terms and conditions of the Plan, the Board
    shall have full and final authority to:

 

    (i) designate Grantees,

 

    (ii) determine the type or types of Awards to be made to a
    Grantee,

 

    (iii) determine the number of shares of Stock to be subject
    to an Award,

 

    (iv) establish the terms and conditions of each Award
    (including, but not limited to, the exercise price of any
    Option, the nature and duration of any restriction or condition
    (or provision for lapse thereof) relating to the vesting,
    exercise, transfer, or forfeiture of an Award or the shares of
    Stock subject thereto, and any terms or conditions that may be
    necessary to qualify Options as Incentive Stock Options),

 

    (v) prescribe the form of each Award Agreement evidencing
    an Award, and

 

    (vi) amend, modify, or supplement the terms of any
    outstanding Award. Such authority specifically includes the
    authority, in order to effectuate the purposes of the Plan but
    without amending the Plan, to modify Awards to eligible
    individuals who are foreign nationals or are individuals who are
    employed outside the United States to recognize differences in
    local law, tax policy, or custom. Notwithstanding the foregoing,
    no amendment, modification or supplement of any Award shall,
    without the consent of the Grantee, impair the Grantee’s
    rights under such Award.

 

    The Company may retain the right in an Award Agreement to cause
    a forfeiture of the gain realized by a Grantee on account of
    actions taken by the Grantee in violation or breach of or in
    conflict with any employment agreement, non-competition
    agreement, any agreement prohibiting solicitation of employees
    or clients of the Company or any Affiliate thereof or any
    confidentiality obligation with respect to the Company or any
    Affiliate thereof or otherwise in competition with the Company
    or any Affiliate thereof, to the extent specified in such Award
    Agreement applicable to the Grantee. Furthermore, the Company
    may annul an Award if the Grantee is an employee

    

    A-4

 

    of the Company or an Affiliate thereof and is terminated for
    Cause as defined in the applicable Award Agreement or the Plan,
    as applicable.

 

    Notwithstanding the foregoing, no amendment or modification may
    be made to an outstanding Option or SAR that would be treated as
    a repricing under the rules of the stock exchange on which the
    Stock is listed, without the approval of the stockholders of the
    Company.

 

    3.4.  Deferral Arrangement.

 

    The Board may permit or require the deferral of any award
    payment into a deferred compensation arrangement, subject to
    such rules and procedures as it may establish, which may include
    provisions for the payment or crediting of interest or dividend
    equivalents, including converting such credits into deferred
    Stock equivalents, restricting deferrals to comply with hardship
    distribution rules affecting 401(k) plans. Any such deferrals
    shall be made in a manner that complies with Code
    Section 409A.

 

    3.5.  No Liability.

 

    No member of the Board or of the Committee shall be liable for
    any action or determination made in good faith with respect to
    the Plan or any Award or Award Agreement.

 

    3.6.  Share Issuance/Book-Entry.

 

    Notwithstanding any provision of this Plan to the contrary, the
    issuance of the Stock under the Plan may be evidenced in such a
    manner as the Board, in its discretion, deems appropriate,
    including, without limitation, book-entry registration or
    issuance of one or more Stock certificates.

 

		
	
    4.  
	
    STOCK
    SUBJECT TO THE PLAN

 

    Subject to adjustment as provided in Section 17
    hereof, the maximum number of shares of Stock available for
    issuance under the Plan shall be 5,033,536, which is comprised
    of (i) 4,463,536 plus (ii) 570,000, the number of
    shares that are subject to outstanding awards granted under the
    Company’s 1997 Stock Option Plan (the
    “1997 Plan”) and the Original Plan as of
    September 22, 2008, but only to the extent that such awards
    are forfeited, canceled or settled for cash or expire pursuant
    to their terms after September 22, 2008 without delivery of
    shares of Stock subject thereto. Stock issued or to be issued
    under the Plan shall be authorized but unissued shares; or, to
    the extent permitted by applicable law, issued shares that have
    been reacquired by the Company. If any shares covered by an
    Award are not purchased or are forfeited, or if an Award
    otherwise terminates without delivery of any Stock subject
    thereto, then the number of shares of Stock counted against the
    aggregate number of shares available under the Plan with respect
    to such Award shall, to the extent of any such forfeiture or
    termination, again be available for making Awards under the
    Plan. The number of shares available for issuance under the Plan
    shall be reduced by the number of shares subject to SARs.

 

    The Board shall have the right to substitute or assume Awards in
    connection with mergers, reorganizations, separations, or other
    transactions to which Section 424(a) of the Code applies.
    The number of shares of Stock reserved pursuant to
    Section 4 may be increased by the corresponding
    number of Awards assumed and, in the case of a substitution, by
    the net increase in the number of shares of Stock subject to
    Awards before and after the substitution.

 

    5.  EFFECTIVE
    DATE, DURATION AND AMENDMENTS

 

    5.1.  Effective Date.

 

    The Plan shall be effective as of the Effective Date. After
    June 7, 2007, the effective date of the Original Plan, no
    further awards have been, or will be, made under the 1997 Plan.

 

    5.2.  Term.

 

    The Plan shall terminate automatically ten (10) years after
    the June 7, 2007 and may be terminated on any earlier date
    as provided in Section 5.3.

    

    A-5

 

    5.3.  Amendment and Termination of the Plan.

 

    The Board may, at any time and from time to time, amend,
    suspend, or terminate the Plan as to any shares of Stock as to
    which Awards have not been made. An amendment shall be
    contingent on approval of the Company’s stockholders to the
    extent stated by the Board, required by applicable law or
    required by applicable stock exchange listing requirements. No
    Awards shall be made after termination of the Plan. No
    amendment, suspension, or termination of the Plan shall, without
    the consent of the Grantee, impair rights or obligations under
    any Award theretofore awarded under the Plan.

 

		
	
    6.  
	
    AWARD
    ELIGIBILITY AND LIMITATIONS

 

    6.1.  Service Providers and Other Persons.

 

    Subject to this Section 6, Awards may be made under
    the Plan to: (i) any Service Provider to the Company or of
    any Affiliate, including any Service Provider who is an officer
    or director of the Company, or of any Affiliate, as the Board
    shall determine and designate from time to time and
    (ii) any other individual whose participation in the Plan
    is determined to be in the best interests of the Company by the
    Board.

 

    6.2.  Successive Awards and Substitute Awards.

 

    An eligible person may receive more than one Award, subject to
    such restrictions as are provided herein. Notwithstanding
    Sections 8.1 and 9.1, the Option Price of an
    Option or the grant price of an SAR that is a Substitute Award
    may be less than 100% of the Fair Market Value of a share of
    Common Stock on the original date of grant; provided, that, the
    Option Price or grant price is determined in accordance with the
    principles of Code Section 424 and the regulations
    thereunder.

 

    6.3.  Limitation on Shares of Stock Subject to
    Awards and Cash Awards.

 

    During any time when the Company has a class of equity security
    registered under Section 12 of the Exchange Act:

 

    (i) the maximum number of shares of Stock subject to
    Options or SARs that can be awarded under the Plan to any person
    eligible for an Award under Section 6 hereof is one
    million (1,000,000) per calendar year;

 

    (ii) the maximum number of shares that can be awarded under
    the Plan, other than pursuant to an Option or SARs, to any
    person eligible for an Award under Section 6 hereof
    is one million (1,000,000) per calendar year; and

 

    (iii) the maximum amount that may be earned as an Annual
    Incentive Award or other cash Award in any calendar year by any
    one Grantee shall be $1,500,000 and the maximum amount that may
    be earned as a Performance Award or other cash Award in respect
    of a performance period by any one Grantee shall be $4,500,000.

 

    The preceding limitations in this Section 6.3 are
    subject to adjustment as provided in Section 17
    hereof.

 

		
	
    7.  
	
    AWARD
    AGREEMENT

 

    Each Award granted pursuant to the Plan shall be evidenced by an
    Award Agreement, in such form or forms as the Board shall from
    time to time determine. Award Agreements granted from time to
    time or at the same time need not contain similar provisions but
    shall be consistent with the terms of the Plan. Each Award
    Agreement evidencing an Award of Options shall specify whether
    such Options are intended to be Non-qualified Stock Options or
    Incentive Stock Options, and in the absence of such
    specification such options shall be deemed Non-qualified Stock
    Options.

 

		
	
    8.  
	
    TERMS AND
    CONDITIONS OF OPTIONS

 

    8.1.  Option Price.

 

    The Option Price of each Option shall be fixed by the Board and
    stated in the Award Agreement evidencing such Option. The Option
    Price of each Option shall be at least the Fair Market Value on
    the Grant Date of a share of

    

    A-6

 

    Stock; provided, however, that in the event that a
    Grantee is a Ten Percent Stockholder, the Option Price of
    an Option granted to such Grantee that is intended to be an
    Incentive Stock Option shall be not less than 110 percent
    of the Fair Market Value of a share of Stock on the Grant Date.
    In no case shall the Option Price of any Option be less than the
    par value of a share of Stock.

 

    8.2.  Vesting.

 

    Subject to Sections 8.3 and 17.3 hereof, each Option
    granted under the Plan shall become exercisable at such times
    and under such conditions as shall be determined by the Board
    and stated in the Award Agreement. For purposes of this
    Section 8.2, fractional numbers of shares of Stock
    subject to an Option shall be rounded down to the next nearest
    whole number.

 

    8.3.  Term.

 

    Each Option granted under the Plan shall terminate, and all
    rights to purchase shares of Stock thereunder shall cease, upon
    the expiration of ten years from the date such Option is
    granted, or under such circumstances and on such date prior
    thereto as is set forth in the Plan or as may be fixed by the
    Board and stated in the Award Agreement relating to such Option;
    provided, however, that in the event that the
    Grantee is a Ten Percent Stockholder, an Option granted to
    such Grantee that is intended to be an Incentive Stock Option
    shall not be exercisable after the expiration of five years from
    its Grant Date.

 

    8.4.  Termination of Service.

 

    Each Award Agreement shall set forth the extent to which the
    Grantee shall have the right to exercise the Option following
    termination of the Grantee’s Service. Such provisions shall
    be determined in the sole discretion of the Board, need not be
    uniform among all Options issued pursuant to the Plan, and may
    reflect distinctions based on the reasons for termination of
    Service.

 

    8.5.  Limitations on Exercise of Option.

 

    Notwithstanding any other provision of the Plan, in no event may
    any Option be exercised, in whole or in part, prior to the date
    the Plan is approved by the stockholders of the Company as
    provided herein or after the occurrence of an event referred to
    in Section 17 hereof which results in termination of
    the Option.

 

    8.6.  Method of Exercise.

 

    An Option that is exercisable may be exercised by the
    Grantee’s delivery to the Company of written notice of
    exercise on any business day, at the Company’s principal
    office, on the form specified by the Company. Such notice shall
    specify the number of shares of Stock with respect to which the
    Option is being exercised and shall be accompanied by payment in
    full of the Option Price of the shares for which the Option is
    being exercised plus the amount (if any) of federal
    and/or other
    taxes which the Company may, in its judgment, be required to
    withhold with respect to an Award. The minimum number of shares
    of Stock with respect to which an Option may be exercised, in
    whole or in part, at any time shall be the lesser of
    (i) 100 shares or such lesser number set forth in the
    applicable Award Agreement and (ii) the maximum number of
    shares available for purchase under the Option at the time of
    exercise.

 

    8.7.  Rights of Holders of Options.

 

    Unless otherwise stated in the applicable Award Agreement, an
    individual holding or exercising an Option shall have none of
    the rights of a stockholder (for example, the right to receive
    cash or dividend payments or distributions attributable to the
    subject shares of Stock or to direct the voting of the subject
    shares of Stock ) until the shares of Stock covered thereby are
    fully paid and issued to him. Except as provided in
    Section 17 hereof, no adjustment shall be made for
    dividends, distributions or other rights for which the record
    date is prior to the date of such issuance.

 

    8.8.  Delivery of Stock Certificates.

 

    Promptly after the exercise of an Option by a Grantee and the
    payment in full of the Option Price, such Grantee shall be
    entitled to the issuance of a stock certificate or certificates
    evidencing his or her ownership of the shares of Stock subject
    to the Option.

    

    A-7

 

    8.9.  Transferability of Options.

 

    Except as provided in Section 8.10, during the
    lifetime of a Grantee, only the Grantee (or, in the event of
    legal incapacity or incompetency, the Grantee’s guardian or
    legal representative) may exercise an Option. Except as provided
    in Section 8.10, no Option shall be assignable or
    transferable by the Grantee to whom it is granted, other than by
    will or the laws of descent and distribution.

 

    8.10.  Family Transfers.

 

    If authorized in the applicable Award Agreement, a Grantee may
    transfer, not for value, all or part of an Option which is not
    an Incentive Stock Option to any Family Member. For the purpose
    of this Section 8.10, a “not for value”
    transfer is a transfer which is (i) a gift, (ii) a
    transfer under a domestic relations order in settlement of
    marital property rights; or (iii) a transfer to an entity
    in which more than fifty percent of the voting interests are
    owned by Family Members (or the Grantee) in exchange for an
    interest in that entity. Following a transfer under this
    Section 8.10, any such Option shall continue to be
    subject to the same terms and conditions as were applicable
    immediately prior to transfer. Subsequent transfers of
    transferred Options are prohibited except to Family Members of
    the original Grantee in accordance with this
    Section 8.10 or by will or the laws of descent and
    distribution. The events of termination of Service of
    Section 8.4 hereof shall continue to be applied with
    respect to the original Grantee, following which the Option
    shall be exercisable by the transferee only to the extent, and
    for the periods specified, in Section 8.4.

 

    8.11.  Limitations on Incentive Stock Options.

 

    An Option shall constitute an Incentive Stock Option only
    (i) if the Grantee of such Option is an employee of the
    Company or any Subsidiary of the Company; (ii) to the
    extent specifically provided in the related Award Agreement; and
    (iii) to the extent that the aggregate Fair Market Value
    (determined at the time the Option is granted) of the shares of
    Stock with respect to which all Incentive Stock Options held by
    such Grantee become exercisable for the first time during any
    calendar year (under the Plan and all other plans of the
    Grantee’s employer and its Affiliates) does not exceed
    $100,000. This limitation shall be applied by taking Options
    into account in the order in which they were granted.

 

		
	
    9.  
	
    TERMS AND
    CONDITIONS OF STOCK APPRECIATION RIGHTS

 

    9.1.  Right to Payment and Grant Price.

 

    A SAR shall confer on the Grantee to whom it is granted a right
    to receive, upon exercise thereof, the excess of (A) the
    Fair Market Value of one share of Stock on the date of exercise
    over (B) the grant price of the SAR as determined by the
    Board. The Award Agreement for a SAR shall specify the grant
    price of the SAR, which shall be at least the Fair Market Value
    of a share of Stock on the date of grant. SARs may be granted in
    conjunction with all or part of an Option granted under the Plan
    or at any subsequent time during the term of such Option, in
    conjunction with all or part of any other Award or without
    regard to any Option or other Award; provided that an SAR that
    is granted subsequent to the Grant Date of a related Option must
    have an SAR Price that is no less than the Fair Market Value of
    one share of Stock on the SAR Grant Date.

 

    9.2.  Other Terms.

 

    The Board shall determine at the date of grant or thereafter,
    the time or times at which and the circumstances under which an
    SAR may be exercised in whole or in part (including based on
    achievement of performance goals
    and/or
    future service requirements), the time or times at which SARs
    shall cease to be or become exercisable following termination of
    Service or upon other conditions, the method of exercise, method
    of settlement, form of consideration payable in settlement,
    method by or forms in which Stock will be delivered or deemed to
    be delivered to Grantees, whether or not an SAR shall be in
    tandem or in combination with any other Award, and any other
    terms and conditions of any SAR.

 

    9.3.  Term.

 

    Each SAR granted under the Plan shall terminate, and all rights
    to purchase shares of Stock thereunder shall cease, upon the
    expiration of ten years from the date such SAR is granted, or
    under such circumstances and on such

    

    A-8

 

    date prior thereto as is set forth in the Plan or as may be
    fixed by the Board and stated in the Award Agreement relating to
    such SAR.

 

    9.4.  Transferability of SARS.

 

    Except as provided in Section 9.5, during the
    lifetime of a Grantee, only the Grantee (or, in the event of
    legal incapacity or incompetency, the Grantee’s guardian or
    legal representative) may exercise a SAR. Except as provided in
    Section 9.5, no SAR shall be assignable or
    transferable by the Grantee to whom it is granted, other than by
    will or the laws of descent and distribution.

 

    9.5.  Family Transfers.

 

    If authorized in the applicable Award Agreement, a Grantee may
    transfer, not for value, all or part of a SAR to any Family
    Member. For the purpose of this Section 9.5, a
    “not for value” transfer is a transfer which is
    (i) a gift, (ii) a transfer under a domestic relations
    order in settlement of marital property rights; or (iii) a
    transfer to an entity in which more than fifty percent of the
    voting interests are owned by Family Members (or the Grantee) in
    exchange for an interest in that entity. Following a transfer
    under this Section 9.5, any such SAR shall continue
    to be subject to the same terms and conditions as were
    applicable immediately prior to transfer. Subsequent transfers
    of transferred SARs are prohibited except to Family Members of
    the original Grantee in accordance with this Section 9.5
    or by will or the laws of descent and distribution.

 

		
	
    10.  
	
    TERMS AND
    CONDITIONS OF RESTRICTED STOCK AND STOCK UNITS

 

    10.1.  Grant of Restricted Stock or Stock Units.

 

    Awards of Restricted Stock or Stock Units may be made for no
    consideration (other than par value of the shares which is
    deemed paid by Services already rendered).

 

    10.2.  Restrictions.

 

    At the time a grant of Restricted Stock or Stock Units is made,
    the Board may, in its sole discretion, establish a period of
    time (a “restricted period”) applicable to such
    Restricted Stock or Stock Units. Each Award of Restricted Stock
    or Stock Units may be subject to a different restricted period.
    The Board may, in its sole discretion, at the time a grant of
    Restricted Stock or Stock Units is made, prescribe restrictions
    in addition to or other than the expiration of the restricted
    period, including the satisfaction of corporate or individual
    performance objectives, which may be applicable to all or any
    portion of the Restricted Stock or Stock Units in accordance
    with Section 14.1 and 14.2. Neither
    Restricted Stock nor Stock Units may be sold, transferred,
    assigned, pledged or otherwise encumbered or disposed of during
    the restricted period or prior to the satisfaction of any other
    restrictions prescribed by the Board with respect to such
    Restricted Stock or Stock Units.

 

    10.3.  Restricted Stock Certificates.

 

    The Company shall issue, in the name of each Grantee to whom
    Restricted Stock has been granted, stock certificates
    representing the total number of shares of Restricted Stock
    granted to the Grantee, as soon as reasonably practicable after
    the Grant Date. The Board may provide in an Award Agreement that
    either (i) the Secretary of the Company shall hold such
    certificates for the Grantee’s benefit until such time as
    the Restricted Stock is forfeited to the Company or the
    restrictions lapse, or (ii) such certificates shall be
    delivered to the Grantee, provided, however, that
    such certificates shall bear a legend or legends that comply
    with the applicable securities laws and regulations and makes
    appropriate reference to the restrictions imposed under the Plan
    and the Award Agreement.

 

    10.4.  Rights of Holders of Restricted Stock.

 

    Unless the Board otherwise provides in an Award Agreement,
    holders of Restricted Stock shall have the right to vote such
    Stock and the right to receive any dividends declared or paid
    with respect to such Stock. The Board may provide that any
    dividends paid on Restricted Stock must be reinvested in shares
    of Stock, which may or may not be subject to the same vesting
    conditions and restrictions applicable to such Restricted Stock.
    All distributions, if any, received by a Grantee with respect to
    Restricted Stock as a result of any stock split, stock dividend,
    combination of shares, or other similar transaction shall be
    subject to the restrictions applicable to the original Grant.

    

    A-9

 

    10.5.  Rights of Holders of Stock Units.

 

    10.5.1.  Voting and Dividend Rights.

 

    Holders of Stock Units shall have no rights as stockholders of
    the Company. The Board may provide in an Award Agreement
    evidencing a grant of Stock Units that the holder of such Stock
    Units shall be entitled to receive, upon the Company’s
    payment of a cash dividend on its outstanding Stock, a cash
    payment for each Stock Unit held equal to the per-share dividend
    paid on the Stock. Such Award Agreement may also provide that
    such cash payment will be deemed reinvested in additional Stock
    Units at a price per unit equal to the Fair Market Value of a
    share of Stock on the date that such dividend is paid.

 

    10.5.2.  Creditor’s Rights.

 

    A holder of Stock Units shall have no rights other than those of
    a general creditor of the Company. Stock Units represent an
    unfunded and unsecured obligation of the Company, subject to the
    terms and conditions of the applicable Award Agreement.

 

    10.6.  Termination of Service.

 

    Unless the Board otherwise provides in an Award Agreement or in
    writing after the Award Agreement is issued, upon the
    termination of a Grantee’s Service, any Restricted Stock or
    Stock Units held by such Grantee that have not vested, or with
    respect to which all applicable restrictions and conditions have
    not lapsed, shall immediately be deemed forfeited. Upon
    forfeiture of Restricted Stock or Stock Units, the Grantee shall
    have no further rights with respect to such Award, including but
    not limited to any right to vote Restricted Stock or any right
    to receive dividends with respect to shares of Restricted Stock
    or Stock Units.

 

    10.7.  Purchase of Restricted Stock.

 

    The Grantee shall be required, to the extent required by
    applicable law, to purchase the Restricted Stock from the
    Company at a Purchase Price equal to the greater of (i) the
    aggregate par value of the shares of Stock represented by such
    Restricted Stock or (ii) the Purchase Price, if any,
    specified in the Award Agreement relating to such Restricted
    Stock. The Purchase Price shall be payable in a form described
    in Section 12 or, in the discretion of the Board, in
    consideration for past Services rendered to the Company or an
    Affiliate.

 

    10.8.  Delivery of Stock.

 

    Upon the expiration or termination of any restricted period and
    the satisfaction of any other conditions prescribed by the
    Board, the restrictions applicable to shares of Restricted Stock
    or Stock Units settled in Stock shall lapse, and, unless
    otherwise provided in the Award Agreement, a stock certificate
    for such shares shall be delivered, free of all such
    restrictions, to the Grantee or the Grantee’s beneficiary
    or estate, as the case may be. Neither the Grantee, nor the
    Grantee’s beneficiary or estate, shall have any further
    rights with regard to a Stock Unit once the share of Stock
    represented by the Stock Unit has been delivered.

 

		
	
    11.  
	
    TERMS AND
    CONDITIONS OF UNRESTRICTED STOCK AWARDS

 

    The Board may, in its sole discretion, grant (or sell at par
    value or such other higher purchase price determined by the
    Board) an Unrestricted Stock Award to any Grantee pursuant to
    which such Grantee may receive shares of Stock free of any
    restrictions (“Unrestricted Stock”) under the Plan.
    Unrestricted Stock Awards may be granted or sold as described in
    the preceding sentence in respect of past services and other
    valid consideration, or in lieu of, or in addition to, any cash
    compensation due to such Grantee.

 

		
	
    12.  
	
    FORM OF
    PAYMENT FOR OPTIONS AND RESTRICTED STOCK

 

    12.1.  General Rule.

 

    Payment of the Option Price for the shares purchased pursuant to
    the exercise of an Option or the Purchase Price for Restricted
    Stock shall be made in cash or in cash equivalents acceptable to
    the Company.

    

    A-10

 

    12.2.  Surrender of Stock.

 

    To the extent the Award Agreement so provides, payment of the
    Option Price for shares purchased pursuant to the exercise of an
    Option or the Purchase Price for Restricted Stock may be made
    all or in part through the tender to the Company of shares of
    Stock, which shall be valued, for purposes of determining the
    extent to which the Option Price or Purchase Price has been paid
    thereby, at their Fair Market Value on the date of exercise or
    surrender.

 

    12.3.  Cashless Exercise.

 

    With respect to an Option only (and not with respect to
    Restricted Stock), to the extent permitted by law and to the
    extent the Award Agreement so provides, payment of the Option
    Price for shares purchased pursuant to the exercise of an Option
    may be made all or in part by delivery (on a form acceptable to
    the Board) of an irrevocable direction to a licensed securities
    broker acceptable to the Company to sell shares of Stock and to
    deliver all or part of the sales proceeds to the Company in
    payment of the Option Price and any withholding taxes described
    in Section 18.3.

 

    12.4.  Other Forms of Payment.

 

    To the extent the Award Agreement so provides, payment of the
    Option Price for shares purchased pursuant to exercise of an
    Option or the Purchase Price for Restricted Stock may be made in
    any other form that is consistent with applicable laws,
    regulations and rules.

 

		
	
    13.  
	
    TERMS AND
    CONDITIONS OF DIVIDEND EQUIVALENT RIGHTS

 

    13.1.  Dividend Equivalent Rights.

 

    A Dividend Equivalent Right is an Award entitling the recipient
    to receive credits based on cash distributions that would have
    been paid on the shares of Stock specified in the Dividend
    Equivalent Right (or other award to which it relates) if such
    shares had been issued to and held by the recipient. A Dividend
    Equivalent Right may be granted hereunder to any Grantee. The
    terms and conditions of Dividend Equivalent Rights shall be
    specified in the grant. Dividend equivalents credited to the
    holder of a Dividend Equivalent Right may be paid currently or
    may be deemed to be reinvested in additional shares of Stock,
    which may thereafter accrue additional equivalents. Any such
    reinvestment shall be at Fair Market Value on the date of
    reinvestment. Dividend Equivalent Rights may be settled in cash
    or Stock or a combination thereof, in a single installment or
    installments, all determined in the sole discretion of the
    Board. A Dividend Equivalent Right granted as a component of
    another Award may provide that such Dividend Equivalent Right
    shall be settled upon exercise, settlement, or payment of, or
    lapse of restrictions on, such other award, and that such
    Dividend Equivalent Right shall expire or be forfeited or
    annulled under the same conditions as such other award. A
    Dividend Equivalent Right granted as a component of another
    Award may also contain terms and conditions different from such
    other award.

 

    13.2.  Termination of Service.

 

    Except as may otherwise be provided by the Board either in the
    Award Agreement or in writing after the Award Agreement is
    issued, a Grantee’s rights in all Dividend Equivalent
    Rights or interest equivalents shall automatically terminate
    upon the Grantee’s termination of Service for any reason.

 

		
	
    14.  
	
    TERMS AND
    CONDITIONS OF PERFORMANCE AND ANNUAL INCENTIVE AWARDS

 

    14.1.  Performance Conditions.

 

    The right of a Grantee to exercise or receive a grant or
    settlement of any Award, and the timing thereof, may be subject
    to such performance conditions as may be specified by the Board.
    The Board may use such business criteria and other measures of
    performance as it may deem appropriate in establishing any
    performance conditions, and may exercise its discretion to
    reduce the amounts payable under any Award subject to
    performance conditions, except as limited under
    Sections 14.2 hereof in the case of a Performance
    Award or Annual Incentive Award intended to qualify under Code
    Section 162(m). If and to the extent required under Code
    Section 162(m), any power or authority relating to a
    Performance Award or Annual Incentive Award intended to qualify
    under Code Section 162(m), shall be exercised by the
    Committee and not the Board.

    

    A-11

 

    14.2.  Performance or Annual Incentive Awards
    Granted to Designated Covered Employees.

 

    If and to the extent that the Committee determines that a
    Performance or Annual Incentive Award to be granted to a Grantee
    who is designated by the Committee as likely to be a Covered
    Employee should qualify as “performance-based
    compensation” for purposes of Code Section 162(m), the
    grant, exercise
    and/or
    settlement of such Performance or Annual Incentive Award shall
    be contingent upon achievement of pre-established performance
    goals and other terms set forth in this Section 14.2.

 

    14.2.1.  Performance Goals Generally.

 

    The performance goals for such Performance or Annual Incentive
    Awards shall consist of one or more business criteria and a
    targeted level or levels of performance with respect to each of
    such criteria, as specified by the Committee consistent with
    this Section 14.2. Performance goals shall be
    objective and shall otherwise meet the requirements of Code
    Section 162(m) and regulations thereunder including the
    requirement that the level or levels of performance targeted by
    the Committee result in the achievement of performance goals
    being “substantially uncertain.” The Committee may
    determine that such Performance or Annual Incentive Awards shall
    be granted, exercised
    and/or
    settled upon achievement of any one performance goal or that two
    or more of the performance goals must be achieved as a condition
    to grant, exercise
    and/or
    settlement of such Performance or Annual Incentive Awards.
    Performance goals may differ for Performance or Annual Incentive
    Awards granted to any one Grantee or to different Grantees.

 

    14.2.2.  Business Criteria.

 

    One or more of the following business criteria for the Company,
    on a consolidated basis,
    and/or
    specified subsidiaries or business units of the Company (except
    with respect to the total stockholder return and earnings per
    share criteria), shall be used exclusively by the Committee in
    establishing performance goals for such Performance or Annual
    Incentive Awards: (1) total stockholder return;
    (2) such total stockholder return as compared to total
    return (on a comparable basis) of a publicly available index
    such as, but not limited to, the Standard &
    Poor’s 500 Stock Index; (3) net income;
    (4) pretax earnings; (5) earnings before interest
    expense, taxes, depreciation and amortization; (6) pretax
    operating earnings after interest expense and before bonuses,
    service fees, and extraordinary or special items;
    (7) operating margin; (8) earnings per share;
    (9) return on equity; (10) return on capital;
    (11) return on investment; (12) operating earnings;
    (13) working capital; (14) ratio of debt to
    stockholders’ equity, (15) free cash flow (which is
    calculated by adding capital expenditures to the cash flows from
    operating activities set forth in the Company’s
    consolidated cash flow statement) and (16) revenue.
    Business criteria may be measured on an absolute basis or on a
    relative basis (i.e., performance relative to peer companies)
    and on a GAAP or non-GAAP basis. The Committee may provide, in a
    manner that meets the requirements of Code Section 162(m)
    that any evaluation of performance may include or exclude any of
    the following events that occur during the applicable
    performance period: (a) asset write-downs;
    (b) litigation or claim judgments or settlements;
    (c) the effect of changes in tax laws, accounting
    principles or other laws or provisions affecting reported
    results; (d) any reorganization or restructuring programs;
    (e) extraordinary nonrecurring items; (f) acquisitions
    or divestitures; and (g) foreign exchange gains and losses.

 

    14.2.3.  Timing For Establishing Performance
    Goals.

 

    Performance goals shall be established not later than
    90 days after the beginning of any performance period
    applicable to such Performance or Annual Incentive Awards, or at
    such other date as may be required or permitted for
    “performance-based compensation” under Code
    Section 162(m).

 

    14.2.4.  Settlement of Performance or Annual
    Incentive Awards; Other Terms.

 

    Settlement of such Performance or Annual Incentive Awards shall
    be in cash, Stock, other Awards or other property, in the
    discretion of the Committee. The Committee may, in its
    discretion, reduce the amount of a settlement otherwise to be
    made in connection with such Performance or Annual Incentive
    Awards. The Committee shall specify the circumstances in which
    such Performance or Annual Incentive Awards shall be paid or
    forfeited in the event of termination of Service by the Grantee
    prior to the end of a performance period or settlement of
    Performance Awards.

    

    A-12

 

    14.3.  Written Determinations.

 

    All determinations by the Committee as to the establishment of
    performance goals, the amount of any potential Performance
    Awards and as to the achievement of performance goals relating
    to Performance Awards, and the amount of any potential
    individual Annual Incentive Awards and the amount of final
    Annual Incentive Awards, shall be made in writing in the case of
    any Award intended to qualify under Code Section 162(m). To
    the extent permitted by Section 162(m), the Committee may
    delegate any responsibility relating to such Performance Awards
    or Annual Incentive Awards.

 

    14.4.  Status of Section 14.2 Awards Under
    Code Section 162(m).

 

    It is the intent of the Company that Performance Awards and
    Annual Incentive Awards under Section 14.2 hereof
    granted to persons who are designated by the Committee as likely
    to be Covered Employees within the meaning of Code
    Section 162(m) and regulations thereunder shall, if so
    designated by the Committee, constitute “qualified
    performance-based compensation” within the meaning of Code
    Section 162(m) and regulations thereunder. Accordingly, the
    terms of Section 14.2, including the definitions of
    Covered Employee and other terms used therein, shall be
    interpreted in a manner consistent with Code Section 162(m)
    and regulations thereunder. The foregoing notwithstanding,
    because the Committee cannot determine with certainty whether a
    given Grantee will be a Covered Employee with respect to a
    fiscal year that has not yet been completed, the term Covered
    Employee as used herein shall mean only a person designated by
    the Committee, at the time of grant of Performance Awards or an
    Annual Incentive Award, as likely to be a Covered Employee with
    respect to that fiscal year. If any provision of the Plan or any
    agreement relating to such Performance Awards or Annual
    Incentive Awards does not comply or is inconsistent with the
    requirements of Code Section 162(m) or regulations
    thereunder, such provision shall be construed or deemed amended
    to the extent necessary to conform to such requirements.

 

		
	
    15.  
	
    PARACHUTE
    LIMITATIONS

 

    Notwithstanding any other provision of this Plan or of any other
    agreement, contract, or understanding heretofore or hereafter
    entered into by a Grantee with the Company or any Affiliate,
    except an agreement, contract, or understanding that expressly
    addresses Section 280G or Section 4999 of the Code (an
    “Other Agreement”), and notwithstanding any formal or
    informal plan or other arrangement for the direct or indirect
    provision of compensation to the Grantee (including groups or
    classes of Grantees or beneficiaries of which the Grantee is a
    member), whether or not such compensation is deferred, is in
    cash, or is in the form of a benefit to or for the Grantee (a
    “Benefit Arrangement”), if the Grantee is a
    “disqualified individual,” as defined in
    Section 280G(c) of the Code, any Option, Restricted Stock
    or Stock Unit held by that Grantee and any right to receive any
    payment or other benefit under this Plan shall not become
    exercisable or vested (i) to the extent that such right to
    exercise, vesting, payment, or benefit, taking into account all
    other rights, payments, or benefits to or for the Grantee under
    this Plan, all Other Agreements, and all Benefit Arrangements,
    would cause any payment or benefit to the Grantee under this
    Plan to be considered a “parachute payment” within the
    meaning of Section 280G(b)(2) of the Code as then in effect
    (a “Parachute Payment”) and (ii) if, as a
    result of receiving a Parachute Payment, the aggregate after-tax
    amounts received by the Grantee from the Company under this
    Plan, all Other Agreements, and all Benefit Arrangements would
    be less than the maximum after-tax amount that could be received
    by the Grantee without causing any such payment or benefit to be
    considered a Parachute Payment. In the event that the receipt of
    any such right to exercise, vesting, payment, or benefit under
    this Plan, in conjunction with all other rights, payments, or
    benefits to or for the Grantee under any Other Agreement or any
    Benefit Arrangement would cause the Grantee to be considered to
    have received a Parachute Payment under this Plan that would
    have the effect of decreasing the after-tax amount received by
    the Grantee as described in clause (ii) of the preceding
    sentence, then the Grantee shall have the right, in the
    Grantee’s sole discretion, to designate those rights,
    payments, or benefits under this Plan, any Other Agreements, and
    any Benefit Arrangements that should be reduced or eliminated so
    as to avoid having the payment or benefit to the Grantee under
    this Plan be deemed to be a Parachute Payment.

    

    A-13

 

		
	
    16.  
	
    REQUIREMENTS
    OF LAW

 

    16.1.  General.

 

    The Company shall not be required to sell or issue any shares of
    Stock under any Award if the sale or issuance of such shares
    would constitute a violation by the Grantee, any other
    individual exercising an Option, or the Company of any provision
    of any law or regulation of any governmental authority,
    including without limitation any federal or state securities
    laws or regulations. If at any time the Company shall determine,
    in its discretion, that the listing, registration or
    qualification of any shares subject to an Award upon any
    securities exchange or under any governmental regulatory body is
    necessary or desirable as a condition of, or in connection with,
    the issuance or purchase of shares hereunder, no shares of Stock
    may be issued or sold to the Grantee or any other individual
    exercising an Option pursuant to such Award unless such listing,
    registration, qualification, consent or approval shall have been
    effected or obtained free of any conditions not acceptable to
    the Company, and any delay caused thereby shall in no way affect
    the date of termination of the Award. Without limiting the
    generality of the foregoing, in connection with the Securities
    Act, upon the exercise of any Option or the delivery of any
    shares of Stock underlying an Award, unless a registration
    statement under such Act is in effect with respect to the shares
    of Stock covered by such Award, the Company shall not be
    required to sell or issue such shares unless the Board has
    received evidence satisfactory to it that the Grantee or any
    other individual exercising an Option may acquire such shares
    pursuant to an exemption from registration under the Securities
    Act. Any determination in this connection by the Board shall be
    final, binding, and conclusive. The Company may, but shall in no
    event be obligated to, register any securities covered hereby
    pursuant to the Securities Act. The Company shall not be
    obligated to take any affirmative action in order to cause the
    exercise of an Option or the issuance of shares of Stock
    pursuant to the Plan to comply with any law or regulation of any
    governmental authority. As to any jurisdiction that expressly
    imposes the requirement that an Option shall not be exercisable
    until the shares of Stock covered by such Option are registered
    or are exempt from registration, the exercise of such Option
    (under circumstances in which the laws of such jurisdiction
    apply) shall be deemed conditioned upon the effectiveness of
    such registration or the availability of such an exemption.

 

    16.2.  Rule 16b-3.

 

    During any time when the Company has a class of equity security
    registered under Section 12 of the Exchange Act, it is the
    intent of the Company that Awards pursuant to the Plan and the
    exercise of Options granted hereunder will qualify for the
    exemption provided by
    Rule 16b-3
    under the Exchange Act. To the extent that any provision of the
    Plan or action by the Board does not comply with the
    requirements of
    Rule 16b-3,
    it shall be deemed inoperative to the extent permitted by law
    and deemed advisable by the Board, and shall not affect the
    validity of the Plan. In the event that
    Rule 16b-3
    is revised or replaced, the Board may exercise its discretion to
    modify this Plan in any respect necessary to satisfy the
    requirements of, or to take advantage of any features of, the
    revised exemption or its replacement.

 

		
	
    17.  
	
    EFFECT OF
    CHANGES IN CAPITALIZATION

 

    17.1.  Changes in Stock.

 

    If the number of outstanding shares of Stock is increased or
    decreased or the shares of Stock are changed into or exchanged
    for a different number or kind of shares or other securities of
    the Company on account of any recapitalization,
    reclassification, stock split, reverse split, combination of
    shares, exchange of shares, stock dividend or other distribution
    payable in capital stock, or other increase or decrease in such
    shares effected without receipt of consideration by the Company
    occurring after the Effective Date, the number and kinds of
    shares for which grants of Options and other Awards may be made
    under the Plan shall be adjusted proportionately and accordingly
    by the Company. In addition, the number and kind of shares for
    which Awards are outstanding shall be adjusted proportionately
    and accordingly so that the proportionate interest of the
    Grantee immediately following such event shall, to the extent
    practicable, be the same as immediately before such event. Any
    such adjustment in outstanding Options or SARs shall not change
    the aggregate Option Price or SAR Exercise Price payable with
    respect to shares that are subject to the unexercised portion of
    an outstanding Option or SAR, as applicable, but shall include a
    corresponding proportionate adjustment in the Option Price or
    SAR Exercise Price per share. The conversion of any convertible
    securities of the Company shall not be treated as an increase in
    shares effected without

    

    A-14

 

    receipt of consideration. Notwithstanding the foregoing, in the
    event of any distribution to the Company’s stockholders of
    securities of any other entity or other assets (including an
    extraordinary dividend but excluding a non-extraordinary
    dividend of the Company) without receipt of consideration by the
    Company, the Company shall, in such manner as the Company deems
    appropriate, adjust (i) the number and kind of shares
    subject to outstanding Awards
    and/or
    (ii) the exercise price of outstanding Options and Stock
    Appreciation Rights to reflect such distribution.

 

    17.2.  Reorganization in Which the Company Is the
    Surviving Entity Which does not Constitute a Corporate
    Transaction.

 

    Subject to Section 17.3 hereof, if the Company shall
    be the surviving entity in any reorganization, merger, or
    consolidation of the Company with one or more other entities
    which does not constitute a Corporate Transaction, any Option or
    SAR theretofore granted pursuant to the Plan shall pertain to
    and apply to the securities to which a holder of the number of
    shares of Stock subject to such Option or SAR would have been
    entitled immediately following such reorganization, merger, or
    consolidation, with a corresponding proportionate adjustment of
    the Option Price or SAR Exercise Price per share so that the
    aggregate Option Price or SAR Exercise Price thereafter shall be
    the same as the aggregate Option Price or SAR Exercise Price of
    the shares remaining subject to the Option or SAR immediately
    prior to such reorganization, merger, or consolidation. Subject
    to any contrary language in an Award Agreement evidencing an
    Award, any restrictions applicable to such Award shall apply as
    well to any replacement shares received by the Grantee as a
    result of the reorganization, merger or consolidation. In the
    event of a transaction described in this Section 17.2,
    Stock Units shall be adjusted so as to apply to the securities
    that a holder of the number of shares of Stock subject to the
    Stock Units would have been entitled to receive immediately
    following such transaction.

 

    17.3.  Corporate Transaction.

 

    Subject to the exceptions set forth in the last sentence of this
    Section 17.3 and the last sentence of
    Section 17.4, upon the occurrence of a Corporate
    Transaction:

 

    (i) all outstanding shares of Restricted Stock shall be
    deemed to have vested, and all Stock Units shall be deemed to
    have vested and the shares of Stock subject thereto shall be
    delivered, immediately prior to the occurrence of such Corporate
    Transaction, and

 

    (ii) either of the following two actions shall be taken:

 

    (A) fifteen days prior to the scheduled consummation of a
    Corporate Transaction, all Options and SARs outstanding
    hereunder shall become immediately exercisable and shall remain
    exercisable for a period of fifteen days, or

 

    (B) the Board may elect, in its sole discretion, to cancel
    any outstanding Awards of Options, Restricted Stock, Stock
    Units,
    and/or SARs
    and pay or deliver, or cause to be paid or delivered, to the
    holder thereof an amount in cash or securities having a value
    (as determined by the Board acting in good faith), in the case
    of Restricted Stock or Stock Units, equal to the formula or
    fixed price per share paid to holders of shares of Stock and, in
    the case of Options or SARs, equal to the product of the number
    of shares of Stock subject to the Option or SAR (the “Award
    Shares”) multiplied by the amount, if any, by which
    (I) the formula or fixed price per share paid to holders of
    shares of Stock pursuant to such transaction exceeds
    (II) the Option Price or SAR Exercise Price applicable to
    such Award Shares.

 

    With respect to the Company’s establishment of an exercise
    window, (i) any exercise of an Option or SAR during such
    fifteen-day
    period shall be conditioned upon the consummation of the event
    and shall be effective only immediately before the consummation
    of the event, and (ii) upon consummation of any Corporate
    Transaction the Plan, and all outstanding but unexercised
    Options and SARs shall terminate. The Board shall send written
    notice of an event that will result in such a termination to all
    individuals who hold Options and SARs not later than the time at
    which the Company gives notice thereof to its stockholders. This
    Section 17.3 shall not apply to any Corporate
    Transaction to the extent that provision is made in writing in
    connection with such Corporate Transaction for the assumption or
    continuation of the Options, SARs, Stock Units and Restricted
    Stock theretofore granted, or for the substitution for such
    Options, SARs, Stock Units and Restricted Stock for new common
    stock options and stock

    

    A-15

 

    appreciation rights and new common stock, stock units and
    restricted stock relating to the stock of a successor entity, or
    a parent or subsidiary thereof, with appropriate adjustments as
    to the number of shares (disregarding any consideration that is
    not common stock) and option and stock appreciation right
    exercise prices, in which event the Plan, Options, SARs, Stock
    Units and Restricted Stock theretofore granted shall continue in
    the manner and under the terms so provided.

 

    17.4.  Adjustments.

 

    Adjustments under this Section 17 related to shares
    of Stock or securities of the Company shall be made by the
    Board, whose determination in that respect shall be final,
    binding and conclusive. No fractional shares or other securities
    shall be issued pursuant to any such adjustment, and any
    fractions resulting from any such adjustment shall be eliminated
    in each case by rounding downward to the nearest whole share.
    The Board shall determine the effect of a Corporate Transaction
    upon Awards other than Options, SARs, Stock Units and Restricted
    Stock, and such effect shall be set forth in the appropriate
    Award Agreement. The Board may provide in the Award Agreements
    at the time of grant, or any time thereafter with the consent of
    the Grantee, for different provisions to apply to an Award in
    place of those described in Sections 17.1, 17.2 and
    17.3.

 

    17.5.  No Limitations on Company.

 

    The making of Awards pursuant to the Plan shall not affect or
    limit in any way the right or power of the Company to make
    adjustments, reclassifications, reorganizations, or changes of
    its capital or business structure or to merge, consolidate,
    dissolve, or liquidate, or to sell or transfer all or any part
    of its business or assets.

 

		
	
    18.  
	
    GENERAL
    PROVISIONS

 

    18.1.  Disclaimer of Rights.

 

    No provision in the Plan or in any Award or Award Agreement
    shall be construed to confer upon any individual the right to
    remain in the employ or service of the Company or any Affiliate,
    or to interfere in any way with any contractual or other right
    or authority of the Company either to increase or decrease the
    compensation or other payments to any individual at any time, or
    to terminate any employment or other relationship between any
    individual and the Company. In addition, notwithstanding
    anything contained in the Plan to the contrary, unless otherwise
    stated in the applicable Award Agreement, no Award granted under
    the Plan shall be affected by any change of duties or position
    of the Grantee, so long as such Grantee continues to be a
    director, officer, consultant or employee of the Company or an
    Affiliate. The obligation of the Company to pay any benefits
    pursuant to this Plan shall be interpreted as a contractual
    obligation to pay only those amounts described herein, in the
    manner and under the conditions prescribed herein. The Plan
    shall in no way be interpreted to require the Company to
    transfer any amounts to a third party trustee or otherwise hold
    any amounts in trust or escrow for payment to any Grantee or
    beneficiary under the terms of the Plan.

 

    18.2.  Nonexclusivity of the Plan.

 

    Neither the adoption of the Plan nor the submission of the Plan
    to the stockholders of the Company for approval shall be
    construed as creating any limitations upon the right and
    authority of the Board to adopt such other incentive
    compensation arrangements (which arrangements may be applicable
    either generally to a class or classes of individuals or
    specifically to a particular individual or particular
    individuals) as the Board in its discretion determines
    desirable, including, without limitation, the granting of stock
    options otherwise than under the Plan.

 

    18.3.  Withholding Taxes.

 

    The Company or an Affiliate, as the case may be, shall have the
    right to deduct from payments of any kind otherwise due to a
    Grantee any federal, state, or local taxes of any kind required
    by law to be withheld with respect to the vesting of or other
    lapse of restrictions applicable to an Award or upon the
    issuance of any shares of Stock upon the exercise of an Option
    or pursuant to an Award. At the time of such vesting, lapse, or
    exercise, the Grantee shall pay to the Company or the Affiliate,
    as the case may be, any amount that the Company or the Affiliate
    may reasonably determine to be necessary to satisfy such
    withholding obligation. Subject to the prior approval of the
    Company or the Affiliate, which may be withheld by the Company
    or the Affiliate, as the case may be, in its sole discretion,
    the Grantee may elect to satisfy such obligations, in whole or
    in part, (i) by causing the Company or the

    

    A-16

 

    Affiliate to withhold shares of Stock otherwise issuable to the
    Grantee or (ii) by delivering to the Company or the
    Affiliate shares of Stock already owned by the Grantee. The
    shares of Stock so delivered or withheld shall have an aggregate
    Fair Market Value equal to such withholding obligations. The
    Fair Market Value of the shares of Stock used to satisfy such
    withholding obligation shall be determined by the Company or the
    Affiliate as of the date that the amount of tax to be withheld
    is to be determined. A Grantee who has made an election pursuant
    to this Section 18.3 may satisfy his or her
    withholding obligation only with shares of Stock that are not
    subject to any repurchase, forfeiture, unfulfilled vesting, or
    other similar requirements. The maximum number of shares of
    Stock that may be withheld from any Award to satisfy any
    federal, state or local tax withholding requirements upon the
    exercise, vesting, lapse of restrictions applicable to such
    Award or payment of shares pursuant to such Award, as
    applicable, cannot exceed such number of shares having a Fair
    Market Value equal to the minimum statutory amount required by
    the Company to be withheld and paid to any such federal, state
    or local taxing authority with respect to such exercise,
    vesting, lapse of restrictions or payment of shares.

 

    18.4.  Captions.

 

    The use of captions in this Plan or any Award Agreement is for
    the convenience of reference only and shall not affect the
    meaning of any provision of the Plan or such Award Agreement.

 

    18.5.  Other Provisions.

 

    Each Award granted under the Plan may contain such other terms
    and conditions not inconsistent with the Plan as may be
    determined by the Board, in its sole discretion.

 

    18.6.  Number and Gender.

 

    With respect to words used in this Plan, the singular form shall
    include the plural form, the masculine gender shall include the
    feminine gender, etc., as the context requires.

 

    18.7.  Severability.

 

    If any provision of the Plan or any Award Agreement shall be
    determined to be illegal or unenforceable by any court of law in
    any jurisdiction, the remaining provisions hereof and thereof
    shall be severable and enforceable in accordance with their
    terms, and all provisions shall remain enforceable in any other
    jurisdiction.

 

    18.8.  Governing Law.

 

    The validity and construction of this Plan and the instruments
    evidencing the Awards hereunder shall be governed by the laws of
    the State of Delaware, other than any conflicts or choice of law
    rule or principle that might otherwise refer construction or
    interpretation of this Plan and the instruments evidencing the
    Awards granted hereunder to the substantive laws of any other
    jurisdiction.

 

    18.9.  Section 409A of the Code.

 

    The Board intends to comply with Section 409A of the Code
    (“Section 409A”), or an exemption to
    Section 409A, with regard to Awards hereunder that
    constitute nonqualified deferred compensation within the meaning
    of Section 409A. To the extent that the Board determines
    that a Grantee would be subject to the additional 20% tax
    imposed on certain nonqualified deferred compensation plans
    pursuant to Section 409A as a result of any provision of
    any Award granted under this Plan, such provision shall be
    deemed amended to the minimum extent necessary to avoid
    application of such additional tax. The nature of any such
    amendment shall be determined by the Board.

 

    ***

    

    A-17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}]]